



- (51) **International Patent Classification:**
C07K 14/315 (2006.01) C12N 9/26 (2006.01)
- (21) **International Application Number:**
PCT/IB2014/062193
- (22) **International Filing Date:**
13 June 2014 (13.06.2014)
- (25) **Filing Language:** Italian
- (26) **Publication Language:** English
- (30) **Priority Data:**
MI2013A000992 17 June 2013 (17.06.2013) IT
- (71) **Applicant:** FIDIA FARMACEUTICI S.P.A. [IT/IT]; Via Ponte della Fabbrica 3/A, I-35031 Abano Terme (PD) (IT).
- (72) **Inventors:** MESSINA, Luciano; c/o Fidia Farmaceutici S.p.A., Via Ponte della Fabbrica 3/A, I-35031 Abano Terme (PD) (IT). MUSUMECI, Luca; c/o Fidia Farmaceutici S.p.A., Via Ponte della Fabbrica 3/A, I-35031 Abano Terme (PD) (IT). VACCARO, Susanna; c/o Fidia Farmaceutici S.p.A., Via Ponte della Fabbrica 3/A, I-35031 Abano Terme (PD) (IT).
- (74) **Agents:** PONTIROLI, Alessandro et al.; c/o Perani & Partners, Piazza San Babila 5, I-20122 Milan (IT).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))



WO 2014/203133 A1

(54) **Title:** BACTERIAL HYALURONIDASE AND PROCESS FOR ITS PRODUCTION

(57) **Abstract:** The present invention relates to a hyaluronidase from *S. koganeiensis*, applications thereof and a method for the production thereof.

TITLE: "BACTERIAL HYALURONIDASE AND PROCESS FOR ITS PRODUCTION"

DESCRIPTION

The present invention relates to a hyaluronidase derived from *S. koganeiensis*, its applications and a method for the production thereof.

Currently, the hyaluronidase used in the clinical field is of animal origin. While this product is suitably purified, it contains a number of contaminants that can induce immunogenic or allergic responses.

Hyaluronic acid is an essential component of the extracellular matrix and a quantitatively significant constituent of the interstitial barrier. Hyaluronidase is a hydrolytic enzyme that cleaves hyaluronic acid in D-glucuronic acid and N-acetyl glucosamine, increasing the permeability of the interstitial matrix. In a variable manner, it is also capable of degrading other acid mucopolysaccharides of the connective tissue. High concentrations of hyaluronidase can be found, for example, in the oral apparatus of leeches, in poison of snakes, bees, scorpions and in the culture supernatant of pathogenic bacteria such as pneumococci, haemolytic streptococci and *Staphylococcus aureus*. In human body, hyaluronidase is found in cornea, in ciliary body, in spleen, in skin and in testicles. High amounts of hyaluronidase are also found in spermatozoa, to which the enzyme allows to go beyond the barrier of hyaluronic acid that protects the ovule.

Hyaluronidase is used in medicine in the treatment of edema, local inflammation, hemorrhoids and chilblains.

Furthermore, it is used in the pharmaceutical field to facilitate the transport and increase the dispersion and diffusion of certain high molecular weight active ingredients (antibodies, drug carrier nanoparticles, DNA for gene therapy, recombinant proteins) administered locally by subcutaneous injection, increasing the bioavailability thereof in amounts comparable to intravenous administration. [1] Previous studies have shown that nanoparticles with diameters up to 200 nm may undergo a strong increase in their transport through the interstitial space when administered concurrently or sequentially with the hyaluronidase enzyme [1]. The studies so far considered show how nanoparticles are able to express, in vitro, their functions, thus showing great potential in the therapeutic and diagnostic fields. However, one should consider, in vivo, the ability of nanoparticles to go beyond barriers due to the type of administration to be used in clinical practice (subcutaneous or gastrointestinal administration or toxicity by intravenous administration), their volume of distribution and their toxicity. The use of nanoparticle and hyaluronidase formulations could therefore represent an excellent and innovative starting point for the therapeutic and diagnostic future with the prospect that the drug carrier nanoparticles may finally be used in common clinical practice by local administration subcutaneously for treatment, for example, in oncology, ophthalmology and osteoarthritis.

Some types of cancer, including pancreas, breast, colon and prostate cancer, have been shown to accumulate high levels of hyaluronic acid (HA). This accumulation of HA

in an abnormal way generates a protection network that surrounds certain types of cancers and supports them. This pathological accumulation of HA with other components of the matrix also increases the pressure of the interstitial fluid of the tumor, tumor vessel constriction, and creates a unique microenvironment that favors the growth of cancer cells as compared to normal cells. These mechanisms generate obstacles to the administration of drugs, inhibiting the potential effectiveness of many anti-cancer agents. By dismantling the HA component that determines the architecture of the tumor, hyaluronidase destroys this tumor microenvironment by opening previously restricted vessels that increase the blood flow to the tumor. This can allow anticancer therapeutic agents to be transported more efficiently to the tumor target, increasing their therapeutic efficacy. Hyaluronidase is also used in cosmetics for the treatment of granulomatous reactions or incorrect collocations, i.e. undesired, of hyaluronic acid, caused by fillers, and to dramatically improve the fibrosis condition present in cellulite.

Hyaluronidase, by segmenting the fibrotic component of cellulite, makes it softer with reduction of the orange peel effect, thus giving a more natural and pleasing appearance to the portion of skin subjected to the treatment. To date, hyaluronidase is the only real treatment, with therapeutic or non-therapeutic purposes, that can fight cellulite with satisfactory results.

Previous studies have shown the efficacy of hyaluronidase in the treatment of cardiovascular diseases such as atherosclerosis [2], but the potential that hyaluronidase

can have on blood pressure was unknown so far [3].

Clinical studies have demonstrated with electrocardiographic tests that these applications are scientifically supported, leading to study the effects that the human serum has on the activity of Wydase, a bovine testicular hyaluronidase that has been widely used in many clinical studies.

The following conclusions emerged from these clinical studies:

- Only the use of a highly purified hyaluronidase has a high clinical value for the reduction of the extent of myocardial infarction [4].
- Many groups have demonstrated that human blood contains a thermolabile inhibitor of bovine hyaluronidase [5,6].

These conclusions, despite the clinical studies have demonstrated the efficacy of hyaluronidase, have not led so far to the development of a hyaluronidase and/or new therapeutic agents based on hyaluronidase capable of ensuring an intravenous administration for the management of cardio- cerebrovascular diseases, limiting the use to some cardiovascular therapies, due to the high value of impurities, with those already available on the market.

In the veterinary field, hyaluronidase is used in solutions comprising antibiotic substances for the treatment of animal diseases, such as bovine mastitis.

To date, the production of bacterial or animal hyaluronidase on an industrial scale has been difficult, both for the low production and for the fact that the enzyme becomes unstable in aqueous solution and loses

activity following purification.

In addition, many of the hyaluronidases produced industrially come from animal extracts (from bovine and ovine testicles) with a high risk of transmitting animal spongiform encephalopathy (the so-called "Mad Cow Disease"). Other industrial productions have produced hyaluronidase (human PH20) in soluble recombinant form starting from mammalian cells, improving the purity and reducing the risk of viral infections. [7] The object of the present invention is to provide a bacterial recombinant hyaluronidase having high purity for pharmaceutical and/or cosmetic applications.

An object of the present invention is to provide an enzyme that is stable in an aqueous solution even for long times and in the presence of proteolytic enzymes, that is completely devoid of the risk of transmitting animal spongiform encephalopathy and that has a high hyaluronidase activity also in the bloodstream without possibility of inhibition or viral or bacterial contamination, so as to allow its use also intravenously. Another object of the present invention is to provide a method for the preparation of hyaluronidase that is efficient, in a high yield and is applicable without difficulty on an industrial scale.

According to the present invention, these objects and others that will be better apparent hereinafter, are achieved by a method for the production of hyaluronidase isolated from *Streptomyces koganeiensis* ATCC 31394 comprising the amino acid sequence shown in SEQ. ID. No. 21 comprising the following steps:

a) inoculating a bacterial culture medium in a bioreactor

with a inoculum of recombinant cells that contain at least one vector comprising the sequence shown as SEQ ID No. 41;

b) subjecting the content of the bioreactor of step a) to fermentation at a pH between 6.7 and 7.1 in the presence of a nourishment solution;

c) adding an inducer of the lac genes to the mixture of step b);

d) subjecting the mixture of step b) to an induction period of between 8 and 24 hours;

e) centrifuging the bacterial cells obtained in step d);

f) re-suspending the pellets obtained in step e) and subjecting the resulting suspension to osmotic shock;

g) extracting the periplasmic proteins by centrifugation of the suspension of step f);

h) purifying the protein fraction having hyaluronidase enzymatic activity obtained in step g) by a sequence of:

i. strong ion-exchange chromatography and isolation of the hyaluronidase enzymatic activity fraction;

ii. weak cation-exchange chromatography and isolation of the hyaluronidase enzymatic activity fraction; and

iii. aromatic hydrophobic interaction chromatography and isolation of the hyaluronidase enzymatic activity fraction.

The objects of the invention are also achieved by a hyaluronidase from *Streptomyces koganeiensis* ATCC 31394 comprising the sequence SEQ ID No: 21, obtainable by said method.

The objects of the invention have also been achieved by a hyaluronidase from *Streptomyces koganeiensis* ATCC 31394 in a purified form and comprising the amino acid sequence

shown in SEQ. ID. No. 21.

The objects of the invention have also been achieved by a polynucleotide comprising the nucleotide sequence shown in SEQ. ID. No. 17, encoding a bacterial hyaluronidase comprising the amino acid sequence in SEQ. ID. No. 21.

The objects of the invention have also been achieved by a genetically engineered recombinant vector comprising said polynucleotide.

The objects of the invention have been achieved by a host cell comprising said genetically engineered recombinant vector.

The objects of the invention are also achieved by a composition suitable for pharmaceutical or cosmetic use comprising said hyaluronidase from *Streptomyces koganeiensis* ATCC 31394 in a purified form and comprising the N-terminal amino acid sequence shown in SEQ. ID. No. 21, said hyaluronidase for use in the treatment and/or prevention of a disorder or disease, optionally in combination with at least another active ingredient, and non-therapeutic use thereof for cosmetic applications and/or for improving the aesthetic appearance.

Within the scope of the present invention, by "composition suitable for pharmaceutical or cosmetic use" means a solid, semisolid or liquid preparation, such as suspension or solution, comprising at least one active ingredient and at least one excipient as is known to the man skilled in the art.

Within the scope of the present invention, the definition of "polypeptide sequence" or "polynucleotide sequence" also includes sequences with a high degree of homology with the sequence indicated. As non-limiting examples,

included within the scope of the invention are polypeptides that have at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity with the sequence shown in SEQ. ID. NO: 21, polynucleotides that have at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity with the sequence shown in SEQ. ID. NO: 17, and polynucleotides that have at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identity with the sequence shown in SEQ. ID. NO: 41.

Within the scope of the present invention, by "hyaluronidase from *Streptomyces koganeiensis* ATCC 31394" it is meant hyaluronidase with a high degree of homology with the hyaluronidase originally isolated from the *Streptomyces koganeiensis* ATCC 31394 organism, that can be produced through biotechnological techniques also from micro-organisms other than *Streptomyces koganeiensis* ATCC 31394 (such as *E. coli* or *B. subtilis*).

If not otherwise stated, within the scope of the present invention the percentages are referred to the weight of a component on the total weight of the composition.

The following figures are provided to better describe the invention, without intending to limit the scope thereof.

Figures.

FIG. 1: production curve of hyaluronidase from supernatant of *Streptomyces koganeiensis* culture relative to the time interval (T). Assay in 1% agarose gel of the profile of total RNA and DNA extracted from *S. koganeiensis* cells during the production step.

FIG. 2: sequence of the amplicon of about 550bp obtained with internal primers MesFor2 and MesRev2 and *in silico* translation of the nucleotide sequence obtained in

protein sequence.

FIG. 3: diagram of the Inverse Polymerase Chain Reaction (IPCR) method used to identify the sequences flanking in 5' and 3' the internal region of the *S. koganeiensis* gene encoding the hyaluronidase.

FIG. 4: complete identification of the entire nucleotide sequence of the gene encoding the CDS hyaluronidase portion of *S. koganeiensis*.

FIG. 5: sequence of the entire gene encoding the CDS hyaluronidase portion *S. koganeiensis* as cloned in the pCR-BluntII-MOUSE vector (Invitrogen).

FIG. 6: (A) BLAST assay for sequence homologies between the amino acid sequence determined by the *S. koganeiensis* ATCC 31394 hyaluronidase and the amino acid sequences reported in web database. The sequences highlighted by the rectangle describe a functional domain of the bacterial hyaluronidase family. (b) BLAST assay for sequence homologies between the nucleotide sequence determined by the *S. koganeiensis* ATCC 31394 hyaluronidase and the nucleotide sequences reported in web database.

FIG. 7: (a) functional characterization on the protein sequence of the hyaluronidase from *S. koganeiensis*. (b) functional characterization on the protein sequence of the hyaluronidase from *Actinoplanes sp.* SE 50/110, *Streptomyces pristinaespiralis* ATCC 25486, *Streptomyces tsukubaensis* NRRL18488.

FIG. 8: DNA fragment encoding hyaluronidase and expression plasmids thereof used for cloning were both cut with established restriction enzymes. The fragments obtained were analyzed in 1% agarose gel and stained with

ethidium bromide. After staining, the gel was acquired by a laboratory image capturing device ImageQuant 300 TL (GE Healthcare) while (quantitative and qualitative) assays were performed using the image analysis software ImageQuant TL (GE Healthcare).

FIG. 9: Screening by PCR and digestion with restriction enzymes, of the DNA fragment encoding the hyaluronidase cloned into expression plasmids. The fragments obtained were analyzed in 1% agarose gel with the image analysis software ImageQuant TL (GE Healthcare) after staining with ethidium bromide and acquisition.

FIG. 10: the figure shows the map of the pHTsk_HYAL plasmid: Pgrac promoter, lacI gene (lacI repressor), Amp^R gene for resistance to ampicillin, Cm^R gene for resistance to chloramphenicol, ColE1 origin of replication of *E. coli*, SamyQ signal peptide of amyQ and hyaluronidase gene encoding the *S. koganeiensis* hyaluronidase, BamHI and XbaI unique restriction sites used for cloning hyaluronidase.

FIG. 11: the figure shows the map of the pHyal_sk plasmid: ori origin of replication of *E. coli*, Ap gene for ampicillin resistance, T7 promoter, lacI gene (lacI repressor), pelB signal peptide, hyaluronidase gene encoding the *S. koganeiensis* hyaluronidase, NcoI and EcoRI unique restriction sites used for cloning the hyaluronidase.

FIG. 12: the figure shows the map of the pHyal_sk_SL plasmid: ori origin of replication of *E. coli*, Ap gene for ampicillin resistance, T7 promoter, lacI gene (lacI repressor), hyaluronidase gene encoding the *S. koganeiensis* hyaluronidase, NdeI and EcoRI unique

restriction sites used for cloning the hyaluronidase.

FIG. 13: (a) the figure shows the nucleotide sequence of the Open Reading Frame (ORF) encoding the hyaluronidase protein of *S. koganeiensis* cloned into vector pHT43 (MOBITEC). (b) the figure shows the nucleotide sequence of the ORF encoding the hyaluronidase protein of *S. koganeiensis* cloned into vector pET22b(+) (Novagen). (c) the figure shows the nucleotide sequence of the ORF encoding the hyaluronidase protein of *S. koganeiensis* cloned into vector pET21b(+) (Novagen).

FIG. 14: assessment in SDS-PAGE at 12% of the expression of the hyaluronidase recombinant (*E. coli*, BL21 (DE3) containing plasmid pHyal_sk) after induction with 1 mM IPTG compared to the protein profile of the pre-induced sample.

FIG. 15: assessment in SDS-PAGE at 12% of the expression of the hyaluronidase recombinant (*E. coli*, BL21 (DE3) containing plasmid pHyal_sk_SL) after induction with 1 mM IPTG compared to the protein profile of the pre-induced sample.

FIG. 16: protein profile in SDS-PAGE at 12% of the fractions obtained after each purification step according to the invention.

FIG. 17: (a) comparison of spectra at the circular dichroism of autologous and recombinant hyaluronidase. (b) the respective UV spectra for the purified recombinant are shown. The UV spectra were analyzed before (upper line) and after (lower line) centrifugation in order to remove any aggregates present.

FIG. 18: molecular weight determination by mass spectrometry of the recombinant hyaluronidase obtained

according to invention.

FIG. 19: determination of the isoelectric point of the recombinant hyaluronidase obtained according to the invention.

FIG. 20: capillary electrophoresis electropherogram of the sample of purified recombinant hyaluronidase according to the invention. The calculated concentration was approximately 1 mg/ml with 100% purity.

FIG. 21: analysis of the purity of the purified recombinant hyaluronidase according to the invention by means of (a) HPLC on gel filtration column Bio-Sil SEC, (b) RP-HPLC on a hydrophobic phase (reversed) column.

FIG. 22: SDS-PAGE 12% - the recombinant hyaluronidase produced and purified according to invention was charged with 1000, 500, 250, 100, and 50 units per lane and compared with 50, 25 and 10 units per lane of hyaluronidase from bovine testicles. Western blot analysis on the preparation of 25 units of the bovine hyaluronidase using the anti-hyaluronidase polyclonal antibody (Abnova), that revealed a single immunoreactive hyaluronidase band.

FIG. 23: electrophoresis in 1% agarose gel shows the depolymerization of the hyaluronic acid purified with 1 unit of recombinant hyaluronidase produced according to the invention at the times indicated ranging from 5 minutes to 24 hours.

FIG. 24: Stability of the recombinant hyaluronidase produced according to the invention and of the hyaluronidase from bovine testicles, against proteolytic enzymes.

FIG. 25: in vitro evaluation of the inhibition effect

that the human and animal serum has on the enzyme activity of hyaluronidase (recombinant produced according to this invention and bovine hyaluronidase).

In one embodiment, the present invention relates to a method for the production of hyaluronidase isolated from *Streptomyces koganeiensis* ATCC 31394 comprising the amino acid sequence shown in SEQ. ID. No. 21 comprising the following steps:

a) inoculating a bacterial culture medium in a bioreactor with an inoculum of recombinant cells that contain at least one vector comprising the sequence shown as SEQ ID No. 41;

b) subjecting the content of the bioreactor of step a) to fermentation at a pH between 6.7 and 7.1 in the presence of a nourishment solution;

c) adding an inducer of the lac genes to the mixture of step b);

d) subjecting the mixture of step b) to an induction period of between 8 and 24 hours;

e) centrifuging the bacterial cells obtained in step d);

f) re-suspending the pellets obtained in step e) and subjecting the resulting suspension to osmotic shock;

g) extracting the periplasmic proteins by centrifugation of the suspension of step f);

h) purifying the protein fraction having hyaluronidase enzymatic activity obtained in step g) by a sequence of:

- i. strong ion-exchange chromatography and isolation of the hyaluronidase enzymatic activity fraction;
 - ii. weak cation-exchange chromatography and isolation of the hyaluronidase enzymatic activity fraction;
- and

iii. aromatic hydrophobic interaction chromatography and isolation of the hyaluronidase enzymatic activity fraction.

To completely eliminate the risk of transmission of animal spongiform encephalopathy, and since limited sources of hyaluronidase of a microbial origin are available, a bacterial strain was selected and isolated in previous studies capable of producing a high hyaluronidase enzyme activity [8].

The same bacterial strain was successfully used ([9]) for the production of hyaluronidase having all of the peculiar enzymatic features, but above all a degree of purity (> 98%) much higher than that described in [8]. Comparative studies have in fact shown that what is obtained from [8] is actually a mixture of 68 different fractions, of which only one has a hyaluronidase activity. The higher purity of [9] is accompanied by a greater enzymatic activity, evaluated at the same concentration and values of T and pH.

Moreover, additional comparative studies have shown that the hyaluronidase described in [9], in contrast to what described in [8], retains its stability over time up to 24 months, even at different temperatures (5 °C and -20 °C), and is virtually unaffected by the activity of proteolytic enzymes with which it comes in contact after administration.

In order to ensure a better safety in the use of this bacterial enzyme in pharmaceutical applications, the isolated and characterized hyaluronidase from the original bacterial strain in [9] was produced in recombinant form using a non-pathogenic bacterial strain

as a host cell defined as Generally Regarded as Safe (GRAS). The production of the bacterial recombinant from the "GRAS" micro-organism retains efficacy comparable to that of autologous hyaluronidase but with a higher amount of production per liter and with a substantially better profile of purity and safety, including the complete absence of the risk of viral transmission.

The method of the present invention allows to obtain high amounts of a high quality recombinant bacterial hyaluronidase for pharmaceutical applications. The high production of recombinant hyaluronidase in non-pathogenic microorganisms has the same efficacy as the traditional hyaluronidase but with a significantly better safety and profile, including the complete absence of the risk of transmitting animal spongiform encephalopathy.

The present invention describes the isolation of the entire gene encoding the hyaluronidase from the gram-positive bacterium *Streptomyces koganeiensis*, with the subsequent cloning and expression of the CDS fragment (encoding sequence, SEQ ID NO: 22). Furthermore, the present invention provides a method for the preparation in the fermenter, the purification and characterization of the recombinant hyaluronidase encoded and secreted in the periplasmic cell portion in a soluble form.

The recombinant protein thus obtained has a high hyaluronidase activity and has a high stability to proteolytic enzymes, is able to perform the total activity with its maximum bioavailability in the bloodstream without possibility of inhibition and bacterial and viral contamination. In its recombinant soluble form, it proves to be effective for use in

applications not only for the preparation of pharmaceutical compositions in facilitating the subcutaneous administration of active ingredients or injectable fluids but also in therapeutic applications, for example in the treatment of pathologies such as hypertension, myocardial infarction, thrombotic events, cardio- and cerebro-vascular events and tumors, since it is unique with the features described by the invention with reference to all other hyaluronidases available to date.

The productions of known hyaluronidase originate from animal sources having a high risk of transmitting animal spongiform encephalopathy; due to this risk, and to the high instability of the animal-derived hyaluronidase, a bacterial strain is researched, selected and isolated capable of producing a hyaluronidase with a high enzyme activity.

In one aspect, the present invention relates to the isolation of the entire gene encoding the bacterial hyaluronidase (SEQ ID NO: 17) having amino acid sequence SEQ ID NO: 21, coming from the gram-positive bacterium *S. koganeiensis*, the consequent cloning and expression of the nucleotide sequence SEQ ID NO: 22 encoding the mature protein having the sequence SEQ ID NO: 21 in a specific bacterial host (e.g. *E. coli*), recognized to be an organism selected for the expression of recombinant proteins used in therapeutic, diagnostic and industrial applications. The invention describes the production of the protein using the fed-batch method for obtaining, in a fermenter, a high amount of recombinant hyaluronidase secreted in the periplasmic cell portion in a soluble

form. The recombinant hyaluronidase thus produced is subjected to purification using three reproducible chromatographic steps (two ion exchange and one hydrophobic exchange). The enzyme is an innovative suitably purified soluble recombinant bacterial enzyme with a high hyaluronidase activity produced by fermentation of safe bacteria without the use of animal-derived cells and raw materials. Furthermore, the enzyme according to this invention is characterized by a sequence of 217 amino acids, by an isoelectric point (pI) of 5.2 ± 0.5 , by a high stability to proteolytic enzymes, by in vitro stability towards animal and human blood, by a high degree of purity and safety, and by the complete absence of the possibility of viral contamination.

The hyaluronidase according to the invention can be obtained as follows: initially, the strain of *S. koganeiensis* was subjected to fermentation and the extracellular material was obtained from bacterium cells as previously described [9]. During the fermentation process, cell fractions are collected every 3-4 hours to assess the levels of DNA and RNA produced by standard methods (Fig. 1), while the other part of the fraction is stored at -80°C in RNAProtect™ Bacteria Reagent (Qiagen), after being analyzed. At the end of fermentation, the supernatant containing the hyaluronidase was clarified, concentrated, dialyzed, purified and then enriched with the sole hyaluronidase component as previously described [9].

Hyaluronidase from *S. koganeiensis* thus isolated was digested with proteolytic enzymes (trypsin, chymotrypsin, Glu-C) and the fragments obtained after digestion were

separated by HPLC. In this way, the information concerning the primary structure of the isolated hyaluronidase was obtained by sequencing the N-terminal portion of the fragments obtained after enzymatic digestion.

The following amino acid sequences were obtained from the N-terminal sequencing performed:

- AGENGATTTFDGPVA (SEQ ID NO:1)
- RFSADTTIEAAFIKTTSETIHAATIYK (SEQ ID NO:2)
- GYADGSDKDAAALSLDLR (SEQ ID NO:3)
- AQVHIVQR (SEQ ID NO:4)
- IGNAATVPTSVDSSGGG (SEQ ID NO:5)

From the research done in a database, the homology of hyaluronidase from *S. koganeiensis* ATCC 31394 with an aforesaid protein (protein_id = ZP_06911952.1) of *Streptomyces pristinaespiralis* ATCC 25486 was identified. On the basis of the N-terminal sequence of the peptides obtained from the isolated protein according to this invention, it was possible to synthesize the corresponding oligonucleotides, that served to isolate the gene encoding hyaluronidase from the genome of *S. koganeiensis*.

The pellets of bacterial cells from fermentation [9] in the period of exponential production of hyaluronidase (Fig. 1) were treated for extraction and purification of DNA and RNA. The products thus obtained are analyzed qualitatively using a spectrophotometer and quantitatively by electrophoresis in agarose gels [12].

The identified and identical amino acid regions between *S. koganeiensis* and *S. pristinaespiralis* served for designing the oligonucleotides used to isolate an

internal portion of the gene encoding the hyaluronidase from the genomic DNA used as template, yielding a PCR product with a single specific band of approximately 550 bp. The nucleotide sequencing of the fragment provided the sequence (SEQ ID NO: 8) shown in Fig. 2.

The inverse PCR technique (IPCR) was developed and performed to identify the nucleotide regions flanking the gene sequence thus identified (Fig. 3). The IPCR method using the pair of primers SEQ ID NO: 11 and SEQ ID NO: 12 allowed obtaining PCR products, respectively of about 700 and 1400 bp, which, once sequenced, provided accurate information on the entire gene encoding the hyaluronidase of *S. koganeiensis*. With this step, the identification of the nucleotide sequence of interest (SEQ ID NO: 13), shown in (fig. 4) is completed.

A pair of primers designed on the non-coding sequences (SEQ ID NO: 14 and SEQ ID NO: 15) and flanking the entire gene encoding the hyaluronidase are used for the amplification of the entire gene (SEQ ID NO: 16) and the PCR product (fig. 5) was cloned directly into the pCR®-BluntII-TOPO® (Invitrogen) vector in of *E. coli* cells.

From the results obtained from the bioinformatics analysis it was observed that the entire length of the gene encoding the hyaluronidase from *S. koganeiensis* was of 744 bp (SEQ ID NO: 17) and that the length of the peptide sequence was estimated to be 247 amino acids (SEQ ID NO: 18). The gene contains a putative domain (SEQ ID NO: 19) of proteins belonging to the hyaluronidase family (Hyaluronidase_1), as evidenced by the search for homologies on a database. Moreover, the analysis of the sequence (SEQ ID NO: 18) using a specific tool indicated

the presence of a signal sequence (signal peptide) of 30 amino acids (amino acids 1 to 30 (SEQ ID NO: 47), with the cleavage site between amino acid 30 and 31). The mature protein (SEQ ID NO: 21) therefore is 217 amino acids long (corresponding nucleotide sequence 651bp (SEQ ID NO: 22)) and its predicted molecular weight (http://web.expasy.org/compute_pi/) is 21679.96Da.

Finally, BLAST analysis for sequence homologies shows a partial homology between the determined amino acid sequence from hyaluronidase from *S. koganeiensis* ATCC 31394 (SEQ ID NO: 18) with some of the amino acid sequences of hypothetical proteins belonging to the Actinobacteria phylum reported in web database.

There is sequence homology between a region of the sequence (SEQ ID NO: 27 and SEQ ID NO: 52) of the hyaluronidase from *S. koganeiensis* (according to the invention) and one of the modules present in the amino acid domain of murine CD44 that binds the hyaluronic acid (Fig. 7 (a)).

cDNA encoding hyaluronidase from *S. koganeiensis* according to the invention (SEQ ID NO: 41) was amplified by PCR starting from the plasmid pCR-BluntII-TOPO [sk_HYAL] and ligated, after being digested with restriction enzymes, in the different plasmids used according to this invention, for example:

Vector	Primers used	Restriction enzymes	Length nucleotide cloned from (SEQ ID NO: 41)	Plasmid obtained
pHT43	SEQ ID NO:28 5'-gtaGGATCCGCCGGG GAAACGGCGCGACGACGA-3'	BamHI	672bp	pHTsk_HYAL (Fig. 13a)
	SEQ ID NO:29 5'-gacTCTAGATCACGCC GGTGGATCGTCGTGACC-3'	XbaI		
pET22b (+)	SEQ ID NO:32 5'-tggCCATGGCCGGG AGAACGGCGCGACGACGA+3'	NcoI	671bp	pHyal_sk (Fig.13,b)
	SEQ ID NO:33 5'-ctcGAATTctcaCGCC GGTGGATCGTCGTGACC-3'	EcoRI		
pET21b (+)	(SEQ ID NO:36) 5'-ataCATATGGCCGGGA GAACGGCGCGACGACGA-3'	NdeI	672bp	pHyal_sk_ SL (Fig.13,c)
	(SEQ ID NO:37) 5'-ctcGAATTctcaGCCGG TGCGATCGTCGTGACC-3'	EcoRI		
pET24b (+)	(SEQ ID NO:36) 5'-ataCATATGGCCGGGA GAACGGCGCGACGACGA-3'	NdeI	672bp	pRH_sk
	(SEQ ID NO:37) 5'-ctcGAATTctcaGCCGG TGCGATCGTCGTGACC-3'	EcoRI		

After cloning and amplification in cells of *E. coli*

strain DH5a, the genetically engineered vectors were extracted and purified to be separately transformed into bacterial expression cells. The vector pHTsk_HYAL is transformed into cells, made competent, of *Bacillus subtilis* (WB800N-MOBITEC) while vectors pHyal_sk, pHyal_sk_SL and pRH_sk are transformed into cells, made competent, of *E. coli*, strain BL21 (DE3) and/or MG1655. All transformations were carried out by chemical processing [13]. The clones, both of *B.subtilis* and of *E.coli*, found to be positive for the presence of vectors containing the nucleotide fragment of hyaluronidase having the genetically correct cloned sequence (SEQ ID NO: 41) are tested for the ability to express the recombinant hyaluronidase in 500 ml cultures (example: 10.11).

Preferably, in the method according to the present invention the recombinant cell of step a) is selected from a cell of *Escherichia coli* and one of *Bacillus subtilis*.

Master Cell Bank and Working Cell Bank was developed on the producer recombinant strains and the aliquots of these 2ml clones with 15% glycerol were introduced into cryogenic vials immediately stored at -80 °C.

Hyaluronidase according to the invention can be produced in large amounts starting from small fermenters using both Batch (example 13) and Fed-Batch (example 14) culture methods as described in this invention (table 1).
Table 1: Plasmids and cloning strategies used in the present invention

Strain	Plasmide	Plasmide description/ Cloning Strategy	Protein Localization	Production of soluble Hyaluronidase (g/L)
<i>B. subtilis</i> WB800N	pHTsk_HYAL	pHT43(+)-SamyQ- (<i>Bam</i> HI/ <i>XBa</i> I) - Hyaluronidase	Supernatant	N.D.
<i>E. Coli</i> BL21DE3	pHyal_sk	pET22b(+)-pelB- (<i>Nco</i> I/ <i>Eco</i> RI) - Hyaluronidase	Cellular periplasma	~0.1
<i>E. Coli</i> BL21DE3	pHyal_sk_SL	pET21b(+)- (<i>Nde</i> I/ <i>Eco</i> RI) - Hyaluronidase	Cellular periplasma	≥ 2
<i>E. Coli</i> BL21DE3	pETsk_Hyal	pET21b(+)- (<i>Bam</i> HI/ <i>Hind</i> III) - Hyaluronidase-His	Included bodies	≤0.001
<i>E. Coli</i> BL21DE3	pET22Hyal	pET22b(+)-pelB- (<i>Msc</i> I/ <i>Eco</i> RI) - Hyaluronidasecellular periplasma	Cellular periplasma	~0.35
<i>E. Coli</i> MG1655	PHyal_sk	pET22b(+)-pelB- (<i>Nco</i> I/ <i>Eco</i> RI) - Hyaluronidase	Cellular periplasma	N.D.

However the best results in terms of production, stability and repeatability, were found using fermentations with the fed-batch method. Ampicillin, neomycin, kanamycin or chloramphenicol may be used as antibiotic according to the features of the specific vectors.

For example, the clone of *E. coli* "BL21 (DE3)-pHyal_sk_SL" was inoculated starting from a vial (coming from the working cell bank stored at -80 °C) in fresh LB Miller culture medium (ratio 1/20 with respect to the fermentation volume) containing 50µg/ml ampicillin and incubated at 37 °C at 150 rpm for 16-18 hours. The clone coming from the inoculum was grown in the fermenter on a minimum culture medium at pH 6.8.

A glycerol solution was preferably given as feed. During the fermentation process, *E. coli* generates acetic acid (acetate) as an undesirable by-product that has numerous negative effects on the production of recombinant proteins. The amount of acetate which is formed during the fermentation phase is directly related to the amount of glucose consumed by the growing *E. coli* cells [15]. In the present invention, it was found that by using glycerol as a carbon source (non-fermentable low cost carbon source) instead of glucose, an approximately 3-fold increase is obtained in the fed-batch production process for the production of recombinant hyaluronidase. As a non-limiting example, the feed can be provided 6 hours after inoculation up to the nineteenth hour (induction time) with an exponential addition ratio. After induction with Isopropyl β-D-1-thiogalactopyranoside (IPTG), 1mM final solution, the feed can be administered to the culture every hour and in the same amount as the last addition for 5 hours. The induction takes place 24 hours after inoculation and continues for 8-24 hours, typically 12 hours. The bacterial cells are collected after the the induction period, by centrifugation, and stored at -80 °C. The

cells of *E.coli* BL21 (DE3) transformed with the vector pHyal_sk_SL produce the recombinant form in the cell periplasm with a maximum concentration reached of about 2 g per liter of culture and an enzymatic activity greater than 87000 U/ml of culture (7.5×10^7 - 8.7×10^7 IU/l of culture) obtained after 12 hours of induction with 1mM IPTG at 37 °C (Table 2).

Table 2: Result of the fermentation batches of clone rHyal_Sk, carried out for the present invention

Batch	5C11	7C11	9C11	10C11	11C12
Fermentation method	Batch	Fed-batch	Fed-batch	Fed-batch	Fed-batch
Hyaluronidase produced at the end of fermentation (g/L)	0.5	1	1.5	1.2	2.1
Final Biomass (O.D. 600nm)	32.7	42	51.6	64	55
Fermentation volume	8	10	10	10	10
Cellular Pellets (g/L)	81.2	83	116	115	149
Inoculum volume	0.4	0.5	0.5	0.5	1
Inoculum Biomass (O.D. 600nm)	3	3	3	2	2.2
Feed volume (L)	0	1.5	1.5	1.5	2.5

Feed Start (h)	/	6	6	6	6
Induction time (h)	16	12	12	12	12
Plasmide stability at the end of fermentation (%)	100	95	100	100	100
Total duration of fermentation (h)	~22	36	36	36	36

The amount of hyaluronidase produced according to this invention was about 670-750 times higher than the autologous hyaluronidase produced in the fermenter as described in the previous patent [9].

The recombinant protein expressed by *E. coli*, in the different fermentation parameters, was analyzed by electrophoresis run in SDS-PAGE (12%) after staining with Coomassie Brilliant Blue G-250 (BIO-RAD, 161-0406) having a molecular weight of 24kDa, while the enzymatic activity was analyzed by turbidimetric assay [16].

Recombinant hyaluronidase produced in the fermenter by the fed-batch method can be purified by a process comprising at least three chromatographic steps.

In the preparation of the first purification, pellets stored at -80 °C (coming from the fed-batch fermentation of *E.coli* BL21 (DE3) transformed with the vector pHyal_sk_SL) are placed in an amount equivalent to 0.6 liters of fermentation product (approximately equivalent to the range of 80-90g of cellular pellets reflecting approximately a production of 1-1.2 g/L of recombinant

hyaluronidase) to equilibrate for 45 minutes at room temperature.

Once equilibrated, pellets were treated with a fresh solution (5 °C) for the dispersion of the pellet. The resuspended pellets were treated with a solution for osmotic shock to favour the extraction of periplasmic proteins. After the osmotic shock step, the product obtained was centrifuged and the resulting supernatant, once homogenised, is brought to pH 8 and filtered by gravity filters with 0.65µm filters. The concentration of the extracted hyaluronidase was evaluated in SDS-PAGE resulting to be about 750-900mg/total (16-22% of the total periplasmic proteins). The activity of the extracted recombinant hyaluronidase was instead assessed by Dorfman's turbidimetric method.

The protein fraction with hyaluronidase enzymatic activity thus obtained is subjected to strong anion exchange chromatography (example: Q sepharose XL).

The protein fraction with hyaluronidase enzymatic activity thus obtained is concentrated to 100ml using Polyethersulfone (PES) filters with cut-off 5kDa and diluted 10 times with 50 mM sodium acetate buffer at pH 4.

The protein fraction with hyaluronidase enzymatic activity thus obtained was subjected to weak cation exchange chromatography (example: CM-Sepharose® Fast Flow).

The protein fraction with hyaluronidase enzymatic activity thus obtained was concentrated to 100ml using Polyethersulfone (PES) filters with cut-off 5kDa and diluted 10 times with 50 mM sodium phosphate buffer with

1.5 mM ammonium sulphate, pH 7.

The protein fraction with hyaluronidase enzymatic activity thus obtained is subjected to aromatic hydrophobic interaction chromatography (example: phenylsepharose HP) and the eluted proteins from this last chromatographic step were collected in a single fraction having a volume of about 730 ml and subjected to hyaluronidase activity assay. After the analysis of the enzymatic activity, the eluted fraction was subjected to ultrafiltration and dialysis with 10 volumes of PBS 1x (Sigma-P4417) brought to a concentration of approximately 1mg/ml and filtered with 0.2 µm filters, the protein concentration is determined by BCA Protein Assay Reagent Kit (PIERCE).

At the end of the purification process applied on approximately 1L of the fermentation product, approximately 600-650 mg of recombinant hyaluronidase and an enzymatic activity greater than 2.6×10^7 U per liter of purified product from fermentation were obtained (Table 3).

Table 3: Result of the purified recombinant hyaluronidase according to the present invention

Sample		Hyaluronidase (U/ml)	Volume (ml)	Hyaluronidase (total U)	Production (%)	Hyaluronidase Total mg
Fermentation Product	Load	48000	600	4.8×10^7	100	1000
Periplasmic extraction	Eluted	7600	5000	3.8×10^7	80	800
Q-Sepharose® XL	Load	7600	5000	3.8×10^7	100	800

	Eluted	23100	950	2.2×10^7	57.8	462
CM- Sepharose® Fast Flow	Load	23100	1000	2.2×10^7	100	462
	Eluted	57900	380	2.2×10^7	100	462
Phenyl Sepharose® HP	Load	22000	1000	2.2×10^7	100	462
	Eluted	26000	730	1.9×10^7	88.8	410
DIA/Filtration	Load	26000	730	1.9×10^7	100	410
	Conc. and DIA/ Filtr.	48570	350	1.7×10^7	93	381
DIA/Filtration 5k	Load	45300	375	1.7×10^7	100	381
0.22µm Filtr.	Eluted	45000	375	1.69×10^7	99.5	378
Total production per culture litre (%)			35			
Total amounts per culture litre (IU)			2.8×10^7			
Total amounts per culture litre (mg)			630			
Total amounts per pellets gram (IU)			2.1×10^7			
Total amounts per pellets gram (mg)			4.8			

In all fractions with hyaluronidase activity there was a marked protein band at about 24 kDa (Fig. 16), the band was subjected to SDS-PAGE electrophoresis on 12% gel and then to blotting on polyvinylidene difluoride membrane (BIO-RAD) and stained according to the instructions provided by the supplier. The hyaluronidase band was cleaved with a scalpel and loaded into the reaction chamber of the sequencer.

The sequencing of the N-terminal end thus carried out allowed establishing that the recombinant hyaluronidase produced according to the invention from the sample of *E.coli* transformed with the vector pHyal_sk_SL according to the invention provided chromatograms wherein a single N-terminal amino acid sequence was significantly present, allowing reconstructing the experimental sequence shown below: AGENGA (SEQ ID NO: 42).

The enzymatic potential of the hyaluronidase produced according to the invention (*E.coli* transformed with the vector pHyal_sk_SL) was evaluated by comparison with the enzyme activity of autologous hyaluronidase [9], using the enzymatic assay described [9] and the activity value was reported to be in both cases greater than 4×10^4 IU/mg protein.

In addition, in the analysis carried out by circular dichroism (CD), the overlay files black line (autologous hyaluronidase [9]) and gray line (heterologous hyaluronidase according to the invention) have a comparable profile, confirming the same protein structure for both samples (Fig. 17-a).

Compared to the prior art [9], the method according to the present invention allows:

- obtaining hyaluronidase of bacterial origin from a strain of *E.coli* well characterized as safe, rather than from *Streptomyces koganeiensis*, by recombinant technology (in place of that by extractive way) suitable for the production on an industrial scale, with production in the periplasm (in place of in extracellular matrix);
- reaching a surprisingly high maximum hyaluronidase activity, higher than 80000 U per milliliter of culture,

against, for example, 130 U per milliliter of culture supernatant in the method of [9] and, in any case, clearly higher than those obtainable with other known processes;

- obtaining high-purity (>99%) hyaluronidase with only 3 chromatographic steps (instead of 5), with significant economic benefits and reduced processing times.

In another aspect, the present invention relates to a hyaluronidase from *Streptomyces koganeiensis* ATCC 31394 in a purified form and comprising the amino acid sequence shown in SEQ. ID. No. 21.

The protein of the present invention can be isolated and produced from *Streptomyces koganeiensis* or recombinantly produced, for example, from cultures of *E. coli* or *Bacillus subtilis*.

It was surprisingly found that, compared to the known protein from *Streptomyces koganeiensis* [9], the enzyme of the present invention has:

- a higher level of purity (99% versus 98%)
- a lower level of endotoxins (<0.5 U/mg instead of >0.5 U/mg);
- presence of the entire peptide sequence (and the corresponding nucleotide sequence), which does not have cysteine (thus reducing the possibility of yielding aggregates);
- greater stability in solution at 5 °C (100% stability at 24 months versus 94% at 24 months of the protein [9]);
- excellent stability at 20 °C (100% at 24 months), at pH 3-11.5 (tested up to 24 hours);
- maximum activity at physiological pH (around 7) and

body temperature (about 37 °C);

- stability in the blood greater than 90%.

The hyaluronidase according to the present invention is a product derived from genetic engineering; so far, there was no availability of the entire protein-encoding gene, since there was no genomic or protein bank of the *S. koganeiensis* strain. Only with the method developed by the inventors described herein the nucleotide sequence encoding the protein has been identified and isolated. This nucleotide fragment is the first ever isolated and documented DNA sequence from this bacterial strain. At the industrial level, the possibility of being able to obtain the entire sequence of the gene encoding this hyaluronidase with a high enzymatic activity allows its use in different systems such as: vectors, systems of genomic integration and in cells, advantageous for the production and use of the enzyme in the pharmaceutical industry.

A further surprising result of the present invention is the very high yield of the process claimed, which was developed through a complex screening activity with different expression vectors, different types of insertion of the nucleotide fragment encoding the protein into the expression vector (i.e. the insertion of the fragment with some restriction sites with respect to others) and screening of the production in different cell lines. This activity, made even more complex since the nucleotide sequence encoding the protein was not available therefore not allowing to apply what was known to the man skilled in the art, has permitted the identification of the most suitable type of cloning, type

of vector and expression cells for obtaining a production so unexpectedly high. The expression and production model for the recombinant protein according to the invention allows to obtain, at the end of the purification process, a pure protein with an endotoxin level of <0.5 U/mg of protein, using only three chromatographic steps instead of 5 as is in the known process (endotoxins >0.5 U/mg protein) [9].

The suitably purified enzyme is characterized by the assays whose results are listed in table 4.

Table 4. Result of the characterization assays of the recombinant hyaluronidase produced according to the present invention from clone rHyal_Sk.

Analysis	Recombinant hyaluronidase
N-terminal Sequencing Protein Assay (Lowry/BCA) Method	1mg/ml AGENGA
1SDS-Page	>99%
Isoelectric Focusing Theoretical I.P.5.5	90% (I.P.5.2±0.4)
SEC-HPLC	100%
RP-HPLC	>99%
Peptide Mapping (by LC-MS) Identity with reference aminoacid sequence	94% (<90%)
Proprietary HCP Assays for <i>E.coli</i> Limit <100ppm	6.5-8.8ppm
Threshold System (Proprietary DNA assays for <i>E.coli</i> Limit<300pg/mg	19pg/mg

Chromo-LAL	<0.5 U/mg
Molar Extinction Coefficient	12383 L*mol ⁻¹ *cm ⁻¹ ABS 280 (=1g/l) 0.570
Mass Spectrometry of Proteins Theoretical MW	21679.98±0.82 21679.96
In Capillary (Zone) Purity Electrophoresis	100%
Molecular Aggregates(UV250-350 nm analysis)	No aggregate
Solution pH in (1x PBS)	~7.5

Hyaluronidase according to the present invention has those activity and high purity features that are necessary for its use in industrial, diagnostic and therapeutic applications. Furthermore, compared to other hyaluronidases known so far, the hyaluronidase produced according to the present invention has proved to be an enzyme that is able to hydrolyse the hyaluronic acid present in the interstitial matrix, increasing the permeability of the connective tissue and favoring the diffusion and dispersion of the drug, locally administered subcutaneously, into the surrounding tissues with extreme stability without the possibility of being digested by proteolytic enzymes present in the connective tissue, which could easily degrade it, once injected, thus inhibiting its action (figure 24).

In this invention, thanks to the provision of an in vitro experimental model using the turbidimetric method, what had already emerged from previous clinical studies was confirmed, that is, the enzymatic activity of bovine hyaluronidase (bovine PH20) is inhibited by human and/or

animal blood, but it was however found that human and/or animal blood does not inhibit hyaluronidase from recombinant *S.koganeiensis* (Fig. 25).

Therefore, from the studies presented here it was found that the recombinant hyaluronidase of the invention (produced according to the method above or from *S.koganeiensis*) has a high hyaluronidase activity, has a high stability to proteolytic enzymes and is able to perform with its maximum bioavailability the total activity in the bloodstream without possibility of bacterial and viral infections. Therefore, it may find use, alone or in combination with other active principles, in the preparation of pharmaceutical or veterinary compositions destined to the treatment of pathologies where it is necessary or advantageous to degrade the hyaluronic acid present in the organ or tissue affected by the pathology.

Thanks to its high stability in aqueous solution, the hyaluronidase of the invention can also be formulated in the form of water based compositions such as solutions, hydrophilic creams, hydrogels, as well as in the form of lipophilic products such as ointments or oily creams.

In one aspect, the present invention relates to a polynucleotide comprising the nucleotide sequence shown in SEQ. ID. No. 17 which encodes the bacterial hyaluronidase from *Streptomyces koganeiensis* ATCC 31394 comprising the amino acid sequence shown in SEQ. ID. No. 21.

In another embodiment, the present invention relates to a genetically engineered recombinant vector comprising said polynucleotide comprising the nucleotide sequence shown

in SEQ. ID. No. 17.

Preferably, said vector is a plasmid.

In another embodiment, the present invention provides a host cell comprising said vector.

In another aspect, the present invention relates to a composition suitable for pharmaceutical or cosmetic use comprising the hyaluronidase from *Streptomyces koganeiensis* ATCC 31394 in a purified form and comprising the amino acid sequence shown in SEQ. ID. No. 21, obtainable from the above method or by extraction from *Streptomyces koganeiensis*.

In a further embodiment, the present invention relates to the hyaluronidase from *Streptomyces koganeiensis* ATCC 31394 in a purified form and comprising the amino acid sequence shown in SEQ. ID. No. 21, obtainable by the above method or by extraction from *Streptomyces koganeiensis*, for use in the treatment and/or prevention of a disease or disorder, optionally in combination with at least another active principle.

The hyaluronidase of the present invention can be applied both in the medical field and in the veterinary field.

Preferably, hyaluronidase according to the invention is for use in the treatment and/or prevention of at least one among oedemas, inflammatory conditions, chilblains, solid tumors, IgE-mediated allergies, diseases of the oral cavity, spontaneous vitreous haemorrhages, arteriosclerosis, blood pressure disorders, cardio-cerebro vascular disorders such as brain arterial stenosis or stroke or bovine mastitis.

As regards the human use, without intending to be limited to it, the hyaluronidase of the invention can be used for

the preparation of pharmaceutical compositions intended for the treatment of edemas, in particular edemas on a traumatic basis, or inflammatory conditions such as the haemorrhoid syndrome; moreover, it can be used for the preparation of compositions intended for the treatment of chilblains. The hyaluronidase of the invention can also be used in combination with other drugs of which it is necessary or advantageous to increase the bioavailability.

For example, for the treatment of oedemas on a traumatic basis, combinations of the hyaluronidase according to the invention with anticoagulant and/or fibrinolytic agents are particularly advantageous. Such combinations may also possibly contain one or more steroidal or non-steroidal anti-inflammatory agents. Moreover, these compositions may be advantageously associated with sulphated hyaluronic acid, which is known to have, in addition to anti-inflammatory properties, also antithrombotic and anticoagulant properties. Associations of the hyaluronidase according to the invention with other active principles are advantageous also in the case of injectable preparations containing active principles with a particularly high molecular weight, for example monoclonal antibodies, cytokines, enzymes, DNA and drug carrier nanoparticles which are usually administered intravenously; this hyaluronidase allows the administration thereof subcutaneously, according to the so-called EASI (Enzymatically-Augmented Subcutaneous Infusion) procedure, that is used especially for the replacement of fluids in terminal patients, so as to restrict or avoid the nursing care. Hyaluronidase

according to the invention can also be used for the preparation of pharmaceutical compositions intended for the treatment of resistant solid tumors. In fact, by degrading the hyaluronic acid, it lowers the pressure of the interstitial fluids into the tumor mass, thus increasing the blood flow to the tumor and thus increasing the efficiency of transport of therapeutic agents towards their target which slow down or inhibit the tumor growth in a more effective way. For the same reason, it also increases the effectiveness of anticancer active ingredients possibly associated thereto. Therefore, a further aspect of the invention relates to pharmaceutical compositions containing hyaluronidase in combination with one or more anticancer active ingredients, such as Vinca alkaloids (vinblastine, vincristine, vinorelbine) and taxanes (Paclitaxel).

A further therapeutic use of hyaluronidase according to the invention relates to the use in the treatment of IgE-mediated allergic forms with EPD (Enzyme Potentiated Desensitization), which consists in the administration of very low doses of allergens to desensitize individuals sensitive to them. By associating hyaluronidase with an allergen it is possible to increase the effectiveness of the treatment, since the allergen more easily reaches the site of action. Therefore, a further object of the invention consists in pharmaceutical compositions containing hyaluronidase in association with one or more allergens that induce IgE-mediated allergic reactions. Hyaluronidase is also used as a factor of diffusion of drugs for dental use in the treatment of oral diseases, such as local anaesthetics and antibiotics; therefore,

according to a further aspect, the invention relates to pharmaceutical compositions containing hyaluronidase according to the invention in association with one or more local anesthetics or antibiotics.

In ophthalmology, hyaluronidase allows to greatly accelerate the treatment of spontaneous vitreous hemorrhages and can be used, alone or in combination with other active ingredients, in the preparation of pharmaceutical forms for ophthalmic use such as solutions, suspensions, gels, creams and ointments, intended for the treatment of such hemorrhages.

Previous studies have shown the efficacy of hyaluronidase in the treatment of cardiovascular diseases such as atherosclerosis [2] and in the management of blood pressure [3]. Moreover, thanks to the ability of hyaluronidase, produced according to this invention, to perform the total activity in the bloodstream without being inhibited, it can be used also for cardio-cerebrovascular therapies.

On the other hand, as regards the veterinary use, a disease that can be effectively treated with the hyaluronidase of the invention is bovine mastitis; in this case, the hyaluronidase can be administered in combination with antibiotics, such as Penicillin G, I-IV generation cephalosporins and enhanced aminopenicilline. Thanks to its stability in aqueous solution, the hyaluronidase according to the invention can be formulated in aqueous-based products; the choice between an aqueous-based formulation and an oil-based formulation can be made by a man skilled in the art on the basis of common knowledge in the field of pharmaceutical

technology, based on the other ingredients in the composition.

In one embodiment, the present invention relates to the non-therapeutic use of hyaluronidase in a purified form and comprising the amino acid sequence shown in SEQ. ID. No. 21 or obtainable from *Streptomyces koganeiensis* ATCC 31394 or by the method above for cosmetic applications and/or for improving the aesthetic appearance.

Hyaluronidase is also used in cosmetics for the treatment of granulomatus reactions or incorrect, undesired collocations of hyaluronic acid, caused by fillers.

Moreover, today, after studies and investigations, an injectable product based on hyaluronidase has been developed which can dramatically improve the fibrosis condition present in cellulite. Hyaluronidase, by segmenting the fibrotic component of cellulite, makes it softer with reduction of the orange peel effect, thus giving a more natural and pleasing appearance to the portion of skin treated. In this case, hyaluronidase is appropriate for all those people who suffer from cellulite or with little presence of fat mass. And to date, it is the only real therapy capable of opposing cellulite with satisfactory results in aesthetic and/or therapeutic terms.

The present invention includes hyaluronidase as described above for the treatment and/or prevention of cellulite for both therapeutic and non-therapeutic purposes.

Finally, the hyaluronidase according to the invention can be used as a reagent in biochemical assays for the qualitative/quantitative determination of hyaluronic acid.

An embodiment of the present invention is described below in an example given for illustrative and not limiting purpose.

Example 1: Bacterial strain and culture conditions

The *S. koganeiensis* strain was obtained from American Type Culture Collection (ATCC 31394). The extracellular material was obtained from cells of the bacterium as previously described [9]. Briefly, a colony of the microorganism was transferred from ISP Medium 2 agar plates and grown in 500 ml of culture medium [(20 g/l of yeast extract (Organotechnie) and 5 g/l of soya peptone (Solabia), at pH 6.9)] at 30 °C, STIRRING at 150 rpm for about 16 hours. After growth, the culture was used to inoculate a 20 liter fermenter (Biostat U, B.BRAUN) containing 10 liters of special soil [(10 g/l of yeast extract (Organotechnie), 5 g/l peptone soybean (Solabia), 3 g/l of malt extract (Constantine), 3 g/l of dextrin type I (Sigma), 0.2 g/l of antifoam (Sigma)]. Before carrying out the inoculation, the pH was brought to 7.0 with NaOH; during the fermentation, the pH was monitored but not controlled, and the temperature was maintained at 30 °C throughout the fermentation, while stirring was maintained at 300 rpm, with aeration of 1.6 VVM (liters of air/liter of fermentation medium/min). The fermentation had a duration of 48 h, time which coincided with the maximum production of hyaluronidase enzyme activity in the culture supernatant. The culture was sampled daily to assess the growth, viability and concentration of the hyaluronidase produced in the culture supernatant by determination of the enzymatic activity by the Dorfman's method [10]. At various steps,

the cell density was determined by counting under a microscope, measuring the optical density at 600 nm and by counting the colonies on plates of ISP Medium 2 agar (Difco).

Cellular fractions are collected every 3-4 hours, where a part is used to assess the levels of RNA and DNA (Fig. 1) by standard methods, using the spectrophotometer T60 UV-Vis (PG Instruments), the other part of the fraction is stored at -80 °C in RNAprotect Bacteria Reagent (Qiagen). At the end of the fermentation, the culture was centrifuged at 5000rpm for 30 minutes at 4 °C (Sorvall Evolution RC) and filtered with 0.2µm tangential flow polyethersulfone filters so as to eliminate the biomass of *Streptomyces koganeiensis* (which was in the form of rounded hyphal aggregates of 1-4 mm diameter) and to obtain a clarified supernatant containing hyaluronidase. Subsequently, the supernatant was concentrated and dialyzed by tangential filtration as previously described [9].

Example 2: Isolation in FPLC of autologous hyaluronidase
The concentrated and dialyzed supernatant was purified and enriched with hyaluronidase alone as previously described [9]. Briefly, the isolation and characterization of the protein occurred using a proteomic approach supported by a process based on the use of a combination of ion-exchange chromatography columns (GE Healthcare), in sequence: CM-Sepharose FF, HiTrap Q XL and HiTrap SP FF, Resource Q. The individual fractions eluted from the chromatographic columns were tested for their highest hyaluronidase activity using an enzymatic dosage and analyzed in parallel for their

protein content by SDS-PAGE.

Determination of the hyaluronidase activity. The hyaluronidase activity was measured with the modified Dorfman's method [10]. Briefly, the product obtained by the chromatographic process was diluted in 0.03M phosphate buffer, 0.82% NaCl, pH 6.3 and 1ml of the thus obtained solution was mixed with 1ml substrate buffer (0.03M phosphate buffer, NaCl 10.82%, pH 6.3) containing 0.5mg hyaluronic acid. The enzymatic digestion was carried out at 37°C for 30 minutes and at the end of the incubation process, turbidity was generated by adding a 4ml horse serum-based acidic solution (SIGMA). The optical density at 640 nm was measured exactly 30 minutes after the addition of the horse serum acidic solution. A standard of hyaluronidase from mammal testicles (EDQM, FIP Hyaluronidase, H1115000) containing 328 IU/mg was used to construct a standard curve and the activity (in units) of the samples was calculated using this curve.

Electrophoresis and analysis in SDS-PAGE.

The electrophoretic assays on polyacrylamide gel in the presence of sodium dodecyl sulfate (SDS-PAGE) were carried out using Laemmli's method [11] on 12% polyacrylamide gel, using a Mini-PROTEAN 3 (BIO-RAD) according to the manufacturer's instructions. The molecular weight of the purified protein was assessed by comparison with standard low molecular weight proteins (BIO-RAD). The polyacrylamide gels suitably stained with Silver Stain Plus (BIO_RAD) or Coomassie(BIO-RAD) after the electrophoretic run, were acquired by a laboratory image capturing device ImageQuant 300 TL (GE Healthcare), while (quantitative and qualitative) assays were

performed using the image analysis software ImageQuant TL (GE Healthcare).

Example 3: N-terminal sequencing of internal protein fragments

The N-terminal amino acid sequencing was carried out according to Edman's degradation method using an automated protein sequencer in pulsed liquid phase (ABI-Perkin Elmer Mod. 477A). The searches for homology were performed using the BLAST software (National Center for Biotechnology Information at the National Library of Medicine (Bethesda, MD) [28], the search server Broad Institute (<http://www.broadinstitute.org/>) and the ClustalW software (<http://www.ebi.ac.uk/clustalw/>). The signalP (<http://www.cbs.dtu.dk/services/SignalP-2.0/>) and Interproscan (<http://www.ebi.ac.uk/Tools/pfa/iprscan/>) were respectively used to conduct analysis of the signal peptide cleavage site and for the analysis of the protein domain.

The information concerning the primary structure of the isolated hyaluronidase were determined by sequencing the N-terminal portion of the entire protein and fragments obtained after digestion with trypsin, chymotrypsin, Glu-C and separation of the fragments produced by HPLC.

From the N-terminal sequencing carried out, the N-terminal amino acid sequence and the amino acid sequence of internal fragments were identified, and they are shown hereafter in a sequence:

- AGENGATTTFDGPVA (SEQ ID NO:1)
- RFSADTTIEAAFIKTTSETIHAATYK (SEQ ID NO:2)
- GYADGSDKDAAALSLDLR (SEQ ID NO:3)
- AQVHIVQR (SEQ ID NO:4)

- IGNAATVPTSVDSSGGG (SEQ ID NO:5)

A search was performed in the database with the sequences identified and the homology of hyaluronidase from *S. koganeiensis* ATCC 31394 with a predicted protein (protein_id = ZP_06911952.1) of *Streptomyces pristinaespiralis* ATCC 25486 was identified. On the basis of the N-terminal sequence of the peptides obtained from the isolated protein according to this invention, it was possible to synthesize the corresponding oligonucleotides, that served to isolate the gene encoding hyaluronidase from *S. koganeiensis* genome.

Example 4: Identification of the novel hyaluronidase gene
The gene encoding the hyaluronidase was isolated from the DNA from bacterial cells of *Streptomyces koganeiensis*. Briefly, the pellets of the bacterial cells from the fermentation in the period of exponential production of hyaluronidase (Fig. 1), are treated for the extraction and purification of genomic DNA using DNeasy Tissue Kit (Qiagen), while the RNA was extracted with RNeasy Mini Kit (Qiagen). A cDNA library was obtained starting from total RNA using MICROBExpress kit and Poly (A) Tailing kit (Applied Biosystems) to isolate mRNA (messenger RNA) from total RNA and the SMART RACE cDNA Amplification Kit (Clontech) according to the manufacturer's instructions. The products thus obtained are analyzed quantitatively using a spectrophotometer T60 UV-Vis (PG Instruments) and qualitatively by electrophoresis in agarose gels [12].
As described in the previous paragraph, the identical amino acid regions between *S. koganeiensis* and *S. pristinaespiralis* were identified; the following oligonucleotides were designed on nucleotide regions

encoding these identical amino acid residues by the use of online tools and a generic bacterial usage codon: MesFor2 (5'-GGAGAACGGGGCGACGACGACGTTTCG-3' (SEQ ID NO: 6)) corresponding to the peptide present in the N-terminal area (ENGATTF), the antisense MesRev2 (5'-GTCGGCACCGTCGCCGCGTTCCCGAT-3' (SEQ ID NO: 7)) corresponding to the peptide present in the C-terminal area (IGNAATVP).

With these two oligonucleotides, and only on genomic DNA as template, several PCR reactions were performed with KOD polymerase (Toyobo), experimenting different conditions of temperature and using or not DMSO at 4%.

At the end of the various processing steps, a specific PCR product was obtained (conditions: initial denaturation 95 °C 5 min, 96 °C 40 sec, 55 °C, 30 sec annealing, 72 °C 1 min extension, for 40 cycles and 72 °C 10 min), in fact, the PCR only amplifies a specific band of approximately 550 bp. The contiguous of the two sequencing processes of the fragment gave the sequence (SEQ ID NO: 8) shown in Fig. 2. The PCR products were analyzed by electrophoresis in agarose gel. Given the homology between the nucleotide sequences of *S.koganeiensis* and *S.pristinaespiralis*, attention was paid to the non-coding regions flanking the gene being analyzed.

From the online source http://www.broadinstitute.org/annotation/genome/streptomyces_group/GenomeDescriptions.html, the flanking regions of the *S. pristinaespiralis* gene were identified, on which two oligonucleotides were designed (MesExrF: 5'-cgggagaagggtgaacgc-3' (SEQ ID NO:9) and MesExtR: 5'-ctccgcgaccagttcttcg-3' (SEQ ID NO: 10)) to

be used in PCR on the genomic DNA template of *S. koganeiensis*. The PCR conditions were defined from the previous step, maintaining a higher denaturation temperature (96 °C) due to the high GC content of the bacterial genomes.

Given the non-specific results, it was decided to try to use these oligonucleotides in combination with MesFor2 (SEQ ID NO: 6) and MesRev2 (SEQ ID NO: 7) used previously and which gave the expected PCR product. It was found that only the amplification with the oligo MesFor2 and MesExtR gave a clear product of the expected size; by sequencing it with the two primers used in the amplification, the region 3' of the gene being analyzed was identified. The inverse PCR technique (IPCR) was developed and performed to identify the nucleotide regions upstream of the gene sequence identified to date (fig. 3). The IPCR method was performed by the following processing steps:

- a) Digestion of the genomic DNA with restriction enzymes. Three different reactions of enzymatic digestion were set up with the enzymes KpnI NARI, and NotI, of approximately 100 ng of genomic DNA of *S. koganeiensis*.
- b) Ligation of the digested DNA.
- c) Amplification by PCR using the ligation reactions as template, with oligonucleotides that anneal within the region known to date encoding the hyaluronidase of *S. koganeiensis*.

The oligonucleotides used are the following:

MesINTf (5'-GGCATCTACGTCACGGCGACGAAC-3' (SEQ ID NO:11)) and the antisense MesINTr (5'-CGTACCCGCGGTGGGTGATCTTCAG-3' (SEQ ID NO:12)).

The preparations digested with KpnI and Nari gave PCR products, respectively, of about 700 and 1400 bp, which once sequenced provided accurate information on the region 5' flanking the gene of hyaluronidase of *S. koganeiensis*. With this step, the identification of the nucleotide sequence of interest (SEQ ID NO: 13), shown in (fig. 4) is completed.

A pair of primers designed on the non-coding sequences (forward: 5'-accattcggagttgatcggtg-3' (SEQ ID NO: 14) Reverse: 5'-gtcaactgcactgttctctcc-3' (SEQ ID NO: 15)) and flanking the entire gene encoding the hyaluronidase are used for the amplification of the entire gene. The PCR product obtained whose sequence obtained after sequencing (SEQ ID NO: 16) is shown in (fig. 5), is cleaved from the gel after electrophoresis run, purified using the Wizard SV Gel and PCR Clean-Up System (Promega) and cloned directly into the vector pCR®-BluntII-TOPO® (Invitrogen) in *E.coli* cells. Subsequently, the clones which were found to be positive (pCR-BluntII-TOPO[sk_HYAL]) at PCR for the presence of the plasmid containing the hyaluronidase gene were analyzed by sequencing.

Analysis of the deduced protein sequence.

BLAST software was used for conducting homology searches on the GenBank database. While the software ExPASy Translate Tool, available on the web, was used to allow the translation *in silico* of the nucleotide sequence of the isolated gene encoding the hyaluronidase from *S.koganeiensis* in the protein sequence. Finally, the conserved domain for the hyaluronidase activity was verified by the InterProScan software available on the website (<http://www.ebi.ac.uk/Tools/InterProScan/>) (Fig.

7 (a)). From the results obtained it was observed that the entire length of the gene encoding the hyaluronidase from *S. koganeiensis* was of 744 bp (SEQ ID NO: 17) and the length of the peptide sequence was estimated to be 247 amino acids (SEQ ID NO: 18). The gene contains a putative domain (SEQ ID NO: 19) of proteins belonging to hyaluronidase family (Hyaluronidase_1), as evidenced by the search for homologies on the Pfam database. Moreover, the analysis of the sequence (SEQ ID NO: 18) using the specific tool <http://www.cbs.dtu.dk/services/SignalP-1.1/> indicated the presence of a signal sequence (signal peptide) of 30 amino acids (amino acids 1 to 30 (SEQ ID NO: 47)), with the cleavage site between amino acid 30 and 31). The mature protein (SEQ ID NO: 21) then is 217 amino acids long (corresponding to the nucleotide sequence 651bp (SEQ ID NO: 22)) and its molecular weight is predicted (using the tools available on the site http://web.expasy.org/compute_pi/) is 21679.96 Da. Finally, BLAST analysis for sequence homologies shows homology between the amino acid sequence determined for the hyaluronidase *S.koganeiensis* ATCC 31394 (SEQ ID NO: 18) and the amino acid sequences reported in the database on the web: homology with the amino acid sequence of the protein Hyaluronoglucosaminidase (predicted from the analysis of the open reading frames starting from the genomic locus described on the web with code YP_006266806.1) from *Actinoplanes* sp. showing 68% identity/78% similarity, homology with the amino acid sequence of the predicted protein ZP_06911952.1 (predicted by the analysis of the open reading frames starting from the genomic locus described on the web code

ZP_06911952.1) of *Streptomyces pristinaespiralis* ATCC 25486 with 66% identity/77% similarity (SEQ ID NO: 23 and SEQ ID NO: 48) and homology with the amino acid sequence of the hypothetical protein STSU_30255 (predicted from the analysis of the open reading frames starting from the genomic locus described on the web with code ZP_10072726.1) of *Streptomyces tsukubaensis* NRRL18488 (SEQ ID NO: 24 and SEQ ID NO: 49) with 66% identity/80% similarity (Fig. 6 a,b). Given the significant similarity of the functional domain (SEQ ID NO: 25 and SEQ ID NO: 50, SEQ ID NO: 26 and SEQ ID NO: 51) observed with hyaluronidase described by this invention (SEQ ID NO: 19), the entire CDS nucleotide sequence encoding these proteins, which are defined on the web with the terminology of "hypothetical or "predicted", was isolated from the original genomic locus and characterized, permitting to identify them, for the first time, in this invention as hyaluronidase (fig. 7 (b)). However, none of these analyses found the entire exact nucleotide sequence and the amino acid sequence of the hyaluronidase isolated according to the patent reported in the literature.

A sequence homology was present between a region of the sequence (SEQ ID NO: 27 and SEQ ID NO: 52) of hyaluronidase from *S.koganeiensis* according to the invention and one of the modules present in the amino acid domain of murine Cd44 that binds hyaluronic acid (Fig.7 (a)).

Example 5: Cloning of gene encoding hyaluronidase in pHT43 (+)

The cDNA encoding the hyaluronidase from *S. koganeiensis* (SEQ ID NO: 41) was amplified by PCR starting from the

plasmid pCR-BluntII-TOPO[sk_HYAL] extracted and purified from cells of *E.coli* with DNA Purification System Wizard Plus SV Minipreps and using the following primers: sense (5'-gtaGGATCCGCCGGGAGAACGGCGCGACGACGA-3' SEQ ID NO: 28); antisense (5'-gacTCTAGATCACGCCGGTGCATCGTCGTGACC-3' SEQ ID NO: 29). The PCR cycles performed for the amplification were: initial denaturation 96 °C for 5 minutes; 30 cycles of annealing 55 °C for 30 seconds, extension at 72 °C for 1 minute, and following denaturation 96 °C for 40 seconds. The Taq DNA polymerase used for the amplification was DyNAzyme II DNA Polymerase (Finnzymes) (Fig. 8). The amplified product (672bp) was purified by the Kit Wizard SV Gel and PCR Clean-Up System (Promega), digested with BamHI (BioLabs) and XbaI (BioLabs), and ligated using T4 ligase (Ambion) with the vector pHT43 (+) previously digested with BamHI and XbaI (Fig. 8). Once the ligase took place, the vector was transformed inside *E. coli* strain DH5a cells (Invitrogen code 12297-016) by chemical processing. The cells after transformation are plated in LB agar containing ampicillin (50µg/ml) and incubated at 37 °C for 16h. The colonies obtained were analyzed to verify the correct ligase occurred between the hyaluronidase gene fragment and the vector by PCR (initial denaturation at 94 °C for 5 minutes, for 30 cycles: annealing at 55 °C for 30 seconds, extension at 72 °C for 60 seconds, and following denaturation at 94 °C for 1 minute), thanks to the aid of vector-specific primers (Forward:5'- TGTGGAATTGTGAGCGGATA -3' (SEQ ID NO:30), Reverse: 5'- TTCAACCATTGTCCAGGT -3' (SEQ ID NO:31)). The PCR product obtained (927bp) together with the products obtained by digestion of the

vector pHTsk_HYAL [vector with insert] (Fig. 10) with restriction enzymes (BamHI, XbaI), was analyzed by electrophoresis in 1% agarose gel (Fig. 9), using the reference standards for the molecular weight (Φ X174 DNA and λ DNA/HindIII of Fermentas). For the analysis of the correct frame of the gene encoding the hyaluronidase after being ligated with the vector, the sequence of the PCR product is sequenced. The nucleotide sequence obtained (SEQ ID NO: 38) after sequencing (Fig. 13,a) is analyzed using bioinformatics tools such as ClustalW, Translate (Expasy) and Chromas life.

Example 6: Cloning of the gene encoding the hyaluronidase in pET22b (+)

The cDNA encoding the hyaluronidase from *S. koganeiensis* (SEQ ID NO: 41) was amplified by PCR starting from the plasmid PCR-BluntII-TOPO[sk_HYAL] extracted and purified from cells of *E.coli* with DNA Purification System Wizard Plus SV Minipreps and using the following primers: sense (5'- tggCCATGGCCGGGAGAACGGCGCGACGACGA-3' (SEQ ID NO: 32)); antisense (5'- ctcGAATTCTcaCGCCGGTGCATCGTCGTGACC-3' (SEQ ID NO : 33)). PCR cycles performed for the amplification were: initial denaturation at 96 °C for 5 minutes; 30 cycles of annealing at 55 °C for 30 seconds, extension at 72 °C for 1 minute, and following denaturation at 96 °C for 40 seconds. The Taq DNA polymerase used for the amplification was DyNAzyme II DNA Polymerase (Finnzymes) (Fig. 8). The amplified product (671bp) was purified by the Kit Wizard SV Gel and PCR Clean-Up System (Promega), digested with NcoI (BioLabs) and EcoRI (BioLabs), and ligated using T4 ligase (Ambion) with the vector pET22b (+) previously digested with NcoI

and EcoRI (Fig. 8). Once the ligation took place, the vector was transformed into *E. coli* strain DH5a cells (Invitrogen code 12297-016) by chemical processing. The cells after transformation are plated in LB agar containing ampicillin (50µg/ml) and incubated at 37 °C for 16h. The colonies obtained were analyzed to verify the correct ligation occurred between the hyaluronidase gene fragment and the vector by PCR (initial denaturation at 94 °C for 5 minutes, for 30 cycles: annealing at 55 °C for 30 seconds, extension at 72 °C for 60 seconds, and following denaturation 94 °C for 1 minute), thanks to the aid of vector-specific primers (T7-promoter: 5'-TAATACGACTCACTATAGGG-3' (SEQ ID NO : 34), T7-terminator: 5'-GCTAGTTATTGCTCAGCGG-3' (SEQ ID NO : 35)). PCR product obtained (940bp) together with the products obtained by digestion of the vector pHyal_sk [vector with insert] (Fig. 11) with restriction enzymes (NcoI, EcoRI), was analyzed by electrophoresis in 1% agarose gel (Fig. 9), using the reference standards for the molecular weight (ΦX174 DNA and λDNA/HindIII of Fermentas). For the analysis of the correct frame of the gene encoding the hyaluronidase after being ligated with the vector, the sequence of the PCR product is sequenced. The nucleotide sequence obtained (SEQ ID NO: 39) after sequencing (Fig. 13,b) is analyzed using bioinformatics tools such as ClustalW, Translate (ExpASy) and Chromas life.

Example 7: Cloning of the gene encoding the hyaluronidase in pET21b+

The cDNA encoding the hyaluronidase from *S. koganeiensis* (SEQ ID NO: 41) was amplified by PCR starting from the plasmid pCR-BluntII-TOPO[sk_HYAL] extracted and purified

from cells of *E.coli* with DNA Purification System Wizard Plus SV Minipreps and using the following primers: sense (5'-ataCATATGGCCGGGAGAACGGCGCGACGACGA-3' (SEQ ID NO:36)); antisense (5'-ctcGAATTctcaCGCCGGTGCATCGTCGTGACC-3' (SEQ ID NO : 37)). PCR cycles performed for the amplification were: initial denaturation at 96 °C for 5 minutes; 30 cycles of annealing at 55 °C for 30 seconds, extension at 72 °C for 1 minute, and following denaturation 96 °C for 40 seconds. The Taq DNA polymerase used for the amplification was DyNAzyme™ II DNA Polymerase (FINNZYME) (Fig. 8). The amplified product (672bp) was purified by the Kit Wizard SV Gel and PCR Clean-Up System (Promega), digested with NdeI (BioLabs) and EcoRI (BioLabs), and ligated using T4 ligase (Ambion) with the vector pET21b (+) (Novagen) previously digested with NdeI and EcoRI (Fig. 8). Once the ligase took place, the vector was transformed inside *E. coli* strain DH5a cells (Invitrogen code 12297-016) by chemical processing. The cells after transformation are plated in LB agar containing ampicillin (50µg/ml) and incubated at 37 °C for 16h. The colonies obtained were analyzed to verify the correct ligase occurred between the hyaluronidase gene fragment and the vector by PCR (initial denaturation at 94 °C for 5 minutes, for 30 cycles: annealing at 55 °C for 30 seconds, extension at 72 °C for 60 seconds, and following denaturation at 94 °C for 1 minute), thanks to the aid of vector-specific primers (T7-promoter: 5'-TAATACGACTCACTATAGGG-3' (SEQ ID NO:34), T7-terminator: 5'-GCTAGTTATTGCTCAGCGG-3' (SEQ ID NO:35)). The PCR product obtained (874bp) together with the products obtained by digestion of the vector pHyal_sk_SL [vector with insert]

(Fig. 12) with restriction enzymes (NdeI, EcoRI), was analyzed by electrophoresis in 1% agarose gel (Fig. 9), using the reference standards for the molecular weight (Φ X174 DNA and λ DNA/HindIII of Fermentas). For the analysis of the correct frame of the gene encoding the hyaluronidase after being ligated with the vector, the sequence of the PCR product is sequenced. The nucleotide sequence obtained (SEQ ID NO: 40) after sequencing (Fig. 13,c) is analyzed using bioinformatics tools such as ClustalW, Translate (ExpASy) and Chromas life.

Example 8: Host bacterial strains used for cloning and the expression of the hyaluronidase gene from *S.koganeiensis*.

Escherichia coli strain DH5 α (Invitrogen, Genotype: F- ϕ 80lacZ Δ M15 Δ (lacZYA-argF)U169 recA1 endA1 hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 tonA (confers resistance to phage T1) [22], was used as host for the plasmid amplification of the cloning system. This strain is provided by Invitrogen (One Shot Max Efficiency DH5 α -T1R chemically competent *E.coli*, 12297-016). The cells were thawed and cultured in solid medium LB agar (10g/l peptone from casein, 5g/l yeast extract, 10g/l NaCl, 15g/l bacteriological agar) containing 10 mM MgSO₄ and grown for 18h at 37 °C. From the resulting culture, a single colony is taken and grown in TYM broth (tryptone 20g/l, Yeast Extract 5g/l, 20ml 5M NaCl, 1 mM MgSO₄) at 37 °C. From the culture, the resulting cells are chemically treated to obtain chemically competent cells. The cells obtained are portioned and stored at -80 °C in an appropriate storage buffer containing 15% glycerol. The transformations are carried out on this stock of

aliquots.

B. subtilis WB800N (Genotype: nprE aprE epr bpr mpr :: ble nprB :: bsr .vpr wprA :: hyg cm :: neo; NeoR [23]), provided by MOBITEC, is a gram-positive bacterial strain characterized by a deficit of eight proteases, as a result it is a bacterial strain that is used for the production of secreted heterologous proteins. The neomycin resistance gene was also inserted in this gene, taking the nomenclature of WB800N. The cells of this bacterial strain after an appropriate production were made competent, portioned and stored at -80 °C in an appropriate storage buffer containing 15% glycerol. The transformations are carried out on this stock of aliquots.

Escherichia coli strain MG1655 (ATCC number: 12297-016, Genotype: F-lambda-[24,25]), was used as a host in the expression system of the hyaluronidase gene from *S. koganeiensis*. The bacterial strain is provided by the American Type Culture Collection (ATCC). The freeze-dried cells were first cultured in few ml of liquid medium and then in solid medium LB agar (10g/l peptone from casein, 5g/l yeast extract, 10g/l NaCl) containing 10 mM MgSO₄ and grown for 18h at 37 °C. From the resulting culture, a single colony is taken and grown in TYM broth at 37 °C. From the culture, the resulting cells are chemically treated to obtain chemically competent cells. The cells obtained are portioned and stored at -80 °C in an appropriate storage buffer containing 15% glycerol. The transformations are carried out on this stock of aliquots.

Escherichia coli strain BL21 (DE3) (*E. coli* BF-dcm ompT

HSDS (rB - mB-) gal λ (DE3) [26,27]), was used as host for the expression system of the gene encoding the hyaluronidase from *S.koganeiensis*. The bacterial strain is provided by Novagen with code 69450-3. The cells were first cultured in few ml of liquid medium and then in solid medium LB agar (10g/l peptone from casein, 5g/l yeast extract, 10g/l NaCl) containing 10 mM MgSO₄ and grown for 18h at 37 °C. From the resulting culture, a single colony is taken and grown in TYM broth at 37 °C. From the culture, the resulting cells are chemically treated to obtain chemically competent cells. The cells obtained are portioned and stored at -80 °C in an appropriate storage buffer containing 15% glycerol. The transformations are carried out on this stock of aliquots.

Example 9: Transformation of plasmids pHTsk_HYAL, pHyal_sk and pHyal_sk_SL in expression cells.

DH5a cells respectively containing the vectors pHTsk_HYAL, pHyal_sk and pHyal_sk_SL were put in culture in about 6ml of LB broth with ampicillin (50 μ g/ml) and grown for 16-18h. The respective cultures after the growth of the engineered cells are centrifuged at approximately 5000g for 10 minutes. The respective plasmids pHTsk_HYAL, pHyal_sk and pHyal_sk_SL were extracted and purified from the pellet obtained using the kit Wizard Plus SV minipreps DNA Purification System (Promega). The purified vectors pHTsk_HYAL, pHyal_sk and pHyal_sk_SL are separately transformed in expression cells. The first vector is transformed into cells, made competent, of *Bacillus subtilis* (WB800N-MOBITEC) while the other two vectors are transformed into cells, made

competent, of *E. coli*, strain BL21 (DE3) and/or MG1655. All transformations were carried out by chemical processing [13]. The cells of *B. subtilis* and *E. coli* after transformation, respectively, are plated in LB agar containing chloramphenicol (10 μ M) plus neomycin (10 μ M), and in LB agar containing ampicillin (50 μ g/ml) to develop resistance to the antibiotic, and incubated at 37 °C for 16h. The colonies obtained after the respective transformations were analyzed to verify the presence of the correct plasmid within the expression cells, by PCR (initial denaturation at 94 °C for 5 minutes, for 30 cycles: annealing at 55 °C for 30 seconds, extension at 72 °C for 60 seconds and following denaturation at 94 °C for 1 minute), thanks to the aid of species-specific primers (Forward: 5'-TGTGGAATTGTGAGCGGATA-3' (SEQ ID NO: 30), Reverse: 5' TTCAACCATTTGTTCCAGGT -3' (SEQ ID NO: 31)) for the analysis of the successful transformation into *B. subtilis* and to verify the successful transformation in *E. coli*. (T7-promoter: 5'-TAATACGACTCACTATAGGG-3' (SEQ ID NO:34), T7-terminator: 5'-GCTAGTTATTGCTCAGCGG-3' (SEQ ID NO: 35)) The PCR products obtained for the cells transformed with pHTsk_HYAL (927bp), pHyal_sk (940bp) and pHyal_sk_SL (874bp) were analyzed by electrophoresis in 1% agarose gel using reference standards for the molecular weight (Φ X174 DNA and λ DNA/HindIII by Fermentas). For the analysis of the correct frame of the gene encoding the hyaluronidase after being bound to the vector, the sequence of the PCR products is sequenced. The nucleotide sequence obtained after sequencing is analyzed using bioinformatics tools such as Vector NTI Advance 9 (Invitrogen), ClustalW,

Traslate (ExpASy) and Chromas life. (Fig. 13 a,b,c).

Example 10: Assessment of the expression level of the recombinant hyaluronidase.

The clones of *B.subtilis* found to be positive for the presence of vectors containing the nucleotide fragment of hyaluronidase found genetically with the frame sequence for correct expression (SEQ ID NO: 41), are tested for the expression level, and then the cells thus engineered are inoculated into flasks containing 500 ml of LB broth with chloramphenicol (10 μ M, Sigma) and neomycin (10 μ M, Sigma), and incubated at 37 °C at 250 rpm. When the cell growth value reaches OD600nm 0.8, they are brought with IPTG (Sigma, I6758) to a final concentration of 1mM. After 12 hours of induction, the bacterial culture is centrifuged at 7500 rpm for 10 minutes and the culture supernatant is collected to evaluate the expression in *B.subtilis*.

Subsequently, the supernatant from the expression tests in *B.subtilis* was concentrated (20 times) and dialyzed in phosphate buffer 1x by ultrafiltration on special polyethersulfone filters with cut-off of 5kD.

In SDS-PAGE, the expressed recombinant had a molecular weight of about 24 kDa with the maximum expression after induction with 1 mM IPTG at OD600nm 0.8 after 12 hours at 37 °C.

The expression and localization of the expression of hyaluronidase in the cells of *B.subtilis* (SEQ ID NO: 21), in the different clones analyzed, was determined by electrophoresis in SDS-PAGE (12%) after staining with Coomassie Brilliant Blue G-250 (BIO-RAD, 161-0406) and with an appropriate enzyme assay, for example Dorfman's

assay.

Example 11: Assessment of the expression level of recombinant hyaluronidase in *E.coli*

The clones of *E.coli* found to be positive for the respective presence of vectors containing the nucleotide fragment of hyaluronidase found genetically with the frame sequence (SEQ ID NO: 41) for the correct expression (SEQ ID NO: 21) are tested for the expression level, inoculated into flasks containing 500 ml of LB broth with ampicillin (50µg/ml, Sigma) and incubated at 37 °C at 250 rpm. When the cell growth value reaches OD600nm 0.8, they are brought with IPTG (Sigma, I6758) to a final concentration of 1mM. The bacterial cells are harvested after 3-4 hours of induction, by centrifugation at 7500 rpm for 10 minutes. After centrifugation, the bacterial pellet is collected for the assessment of the expression in engineered cells of *E.coli* and to verify in what portion of the cell the recombinant is produced.

Subsequently, the pellets coming from the *E.coli* cells induced with IPTG were treated with B-PER Bacterial Protein (PIERCE) according to the instructions provided by the supplier, to assess the expression of hyaluronidase in the periplasmic and/or cytoplasmic portion and/or forming inclusion bodies. Both clones of *E.coli* respectively containing the plasmids pHyal_sk and pHyal_sk_SL expressed the recombinant in soluble form in the periplasmic portion:

E.coli BL21 (DE3) containing pHyal_sk. In SDS-PAGE, the expressed recombinant has a molecular weight of about 24 kDa, constituting about 40% of the total bacterial proteins after induction at OD600nm 0.8 with 1mM IPTG for

3-4 hours at 37 °C. However, of the amount of expressed recombinant, only 18% (only 7.2% overall) is present in soluble form in the periplasm, the remaining 82% has inclusion bodies (only 32.8% overall). The periplasmic soluble portion turns out to be present at a maximum concentration of 52 µg/ml culture, with an enzymatic activity equal to about 2100 U/ml culture.

E.coli BL21 (DE3) containing pHyal_sk_SL. In SDS-PAGE, the expressed recombinant has a molecular weight of about 24 kDa, constituting about 15% of the total bacterial proteins after induction at OD 600 nm 0.8 with 1mM IPTG for 3-4 hours at 37 °C. Moreover, all the expressed protein is present in soluble form in the periplasm. The periplasmic soluble portion turned out to be present at a concentration of about 125µg/ml culture, with an enzymatic activity greater than 5000 U/ml culture.

Both the expression and localization of the expression of hyaluronidase in the cells of *E.coli* in the different clones analyzed, was determined by electrophoresis in SDS-PAGE (12%) after staining with Coomassie Brilliant Blue G-250 (BIO-RAD, 161-0406) and with an appropriate enzyme assay, for example Dorfman's assay.

Example 12: Development of the Master Cell Bank and Working Cell Bank of recombinant strains

Master Cell Bank (MCB)

Under sterility, a single colony was taken from from the colonies belonging to the producer strain and resuspended in a sterile flask containing 10ml of liquid medium (LB broth with chloramphenicol (10µM, Sigma) and neomycin (10µM, Sigma) as regards the recombinant cells of *B.subtilis* and LB broth with ampicillin (50µg/ml, Sigma)

as regards the recombinant cells of *E.coli*) and incubated at 200rpm at 37 °C for about 16 hours. After the incubation period and after suitable checks on the sterility of the culture, 10ml of each culture were respectively transferred in 100ml of liquid medium (LB broth with chloramphenicol (10µM, Sigma) and neomycin (10µM, Sigma) as regards the recombinant cells of *B.subtilis* and LB broth with ampicillin (50µg/ml, Sigma) as regards the recombinant cells of *E.coli*) and incubated for 5-6 hours at 37 °C at 200rpm. Again, after the incubation period and after appropriate checks on the sterility of the culture, an amount of sterile glycerol was added cold to each culture until reaching a final concentration of glycerol equal to 15%. The mixture is stirred and 2ml aliquots are introduced into cryogenic vials (CORNING, 430659) which are immediately placed at -80 °C.

The development of the Master Cell Bank was performed under sterile conditions for strains: strain *B.subtilis* (WB800N-MoBitec) containing the plasmid engineered with pHTsk_HYAL (clone 105), strain *E.coli* (DH5α) containing the plasmid engineered with pHTsk_HYAL (clone 105), strain *E.coli* (DH5α) and *E.coli* (BL21 (DE3)) containing the plasmid engineered with pHyal_sk (clone 413), strain *E.coli* (DH5α) and *E.coli* (BL21 (DE3)) containing the plasmid engineered with pHyal_sk_SL (clone 225) and strain *E. coli* (DH5α) and *E.coli* (BL21 (DE3)) containing the plasmid engineered with pRH_sk (clone 600).

Working Cell Bank (WCB)

Under sterility, an aliquot was taken from a vial from the Master Cell Bank and tested in solid medium LB broth

with chloramphenicol (10 μ M, Sigma) and neomycin (10 μ M, Sigma) as regards the recombinant cells of *B.subtilis* and LB broth with ampicillin (50 μ g/ml, Sigma) or kanamycin (30 μ g/ml, SIGMA) as regards the recombinant cells of *E.coli*) and incubated at 200rpm at 37 °C for about 18 hours. Under sterile hood, a single colony was taken from the colonies belonging to the producer strain and resuspended in a sterile flask containing 10ml of liquid medium (LB broth with chloramphenicol (10 μ M, Sigma) and neomycin (10 μ M, Sigma) as regards the recombinant cells of *B.subtilis* and LB broth with ampicillin (50 μ g/ml, Sigma) or kanamycin (30 μ g/ml, SIGMA) as regards the recombinant cells of *E.coli*) and incubated at 200rpm at 37 °C for about 16 hours. After the incubation period and after suitable checks on the sterility of the culture, 10ml of each culture were respectively transferred in 100ml of liquid medium (LB broth with chloramphenicol (10 μ M, Sigma) and neomycin (10 μ M, Sigma) as regards the recombinant cells of *B.subtilis* and LB broth with ampicillin (50 μ g/ml, Sigma) or kanamycin (30 μ g/ml, SIGMA) as regards the recombinant cells of *E.coli*) and incubated for 5-6 hours at 37 °C at 200rpm. Again, after the incubation period and after appropriate checks on the sterility of the culture, an amount of sterile glycerol was added cold to each culture until reaching a final concentration of glycerol equal to 15%. The mixture is stirred and 2ml aliquots are introduced into cryogenic vials (CORNING, 430659) which are immediately placed at -80 °C.

The development of Working Cell Bank was carried out under maximum sterility and for the strains: strain

B.subtilis (WB800N-MoBitec) containing the plasmid engineered with pHTsk_HYAL (rhyaluronidase clone 105), *E.coli* (BL21 (DE3)) containing the plasmid engineered with pHyal_sk (hyaluronidase clone 413), strain *E.coli* (BL21 (DE3) containing the plasmid engineered with pHyal_sk_SL (clone rHyal_Sk) and for strain *E.coli* (BL21 (DE3) containing the plasmid engineered with pRH_sk (clone rH_sk).

The following tests were performed both on MCB and on WCB to assess their purity: assessment of the number of copies of the plasmid from the cells of MCB and WCB, analysis of the plasmid by restriction enzymes and separation of the digested fragments by 1% agarose gel, assessment of the conservation of glycerol in cells containing the expression plasmid in the MCB and WCB, evaluation of the stability of the cells containing the expression plasmid in the MCB and WCB, viability of recombinant cells in LB plates, identity of the strains *E.coli*, purity of the culture, Coli phage assay, evaluation of the expression product in SDS-PAGE, sequencing of the region encoding the recombinant protein.

Example 13: Batch fermentations of recombinant hyaluronidase.

The ability of clones of *E.coli* BL21 (DE3) - pHyal_sk and BL21 (DE3)- pHyal_sk_SL to produce the recombinant hyaluronidase was evaluated by growth in fermenters by batch culture.

The inoculum is prepared by inoculating a vial (from the working cell bank stored at -80 °C) in 400 ml of fresh LB

medium (ratio 1/20 with respect to the fermentation volume) containing 50µg/ml ampicillin and incubated at 37 °C at 150 rpm for 16-18 hours. The clones from the respective inocula (*E.coli* BL21 (DE3)-pHyal_sk and BL21 (DE3) - pHyal_sk_SL), were separately grown in the fermenter on a minimum culture medium whose composition per liter was given by: 2g Na₂HPO₄*2H₂O, 2 g KH₂PO₄, 4g K₂HPO₄, 3.8 g citric acid, 3.3g (NH₄)₂SO₄, 40 ml glycerol, 0.6 ml PPG 2000 antifoam (Fluka Code 81380). The pH was corrected after sterilization at 121 °C to 6.8 with a 25% solution of ammonium hydroxide % (SIGMA), and only adding the following components per liter of medium, sterilized by filtration through 0.2µm filters: 0.49 g MgSO₄*7H₂O, 0.0147g CaCl₂, 1ml FeCl₂ (0.2M), 2ml trace elements (trace elements per liter: 0.96g citric acid, 0.25g CoCl₂*6H₂O, 1.5g MnCl₂*4H₂O, 0.15g CuCl₂*2H₂O, 1.5 g H₃BO₃, 0.25g Na₂MoO₄*2H₂O, 1.3 g Zn(CH₃COO)₂*2H₂O), 0.01g thiamine, 5g glucose, 3g yeast extract.

The induction with Isopropyl β-D-1-thiogalactopyranoside (IPTG) occurs 4-6 hours after inoculation and continued for about 16-18 hours. The fermentation parameters developed were as follows: temperature 37 °C, agitation 600rpm, air flow 5-10 liters air per minute and head pressure of about 0.8 bar.

The bacterial cells are harvested after the induction period of about 16 hours by centrifugation at 7500 rpm for 25 minutes. After collection, the bacterial cells are stored at -80 °C, ready to be used for the extraction and purification of recombinant hyaluronidase. The recombinant protein expressed by *E. coli*, in the different fermentation parameters, is analyzed by electrophoresis

run in SDS-PAGE (12%) after staining with Coomassie Brilliant Blue G-250 (BIO-RAD, 161-0406), while the enzyme activity is analyzed by turbidimetric assay [16]. The cells of *E.coli* BL21 (DE3) transformed with the vector pHyal_sk are induced to express the soluble heterologous protein in the periplasm, in the fermenter with 8L of medium. In SDS-PAGE, the expressed recombinant had a molecular weight of about 24 kDa and an amount of protein expressed in the cell periplasm of about 0.1 - 0.15 g/L of culture, the maximum quantity reached after 16 hours of induction with 1mM IPTG at 37 °C.

The cells of *E.coli* BL21 (DE3) transformed with the vector pHyal_sk_SL are induced to express the soluble heterologous protein in the periplasm, in the fermenter with 8L of medium. The periplasmic soluble portion turned out to be present at a concentration of about 0.35-0.5g/L culture, with an enzymatic activity greater than 15050-21495 U/ml culture. In SDS-PAGE, the recombinant expressed had a molecular weight of about 24 kDa, constituting about 18% of the total bacterial proteins, after induction with 1mM IPTG at the sixteenth hour at 37 °C.

For both clones, the stability of the plasmid during fermentation was found to be 100% (Table 2). The stability of the plasmid is monitored until the end of the fermentation by screening with the replica plating technique [29] which allows replication of the colonies on plates containing the antibiotic.

Example 14: Fed-batch fermentations of recombinant hyaluronidase.

The ability of clones of *E. coli* BL21 (DE3) - pHyal_sk and BL21 (DE3)- pHyal_sk_SL to produce the recombinant hyaluronidase was evaluated by growth in fermenters by fed-batch culture.

The inoculum is prepared by inoculating a vial (from the working cell bank stored at -80 °C) in 500 ml of fresh LB medium (ratio 1/20 with respect to the fermentation volume) containing 50µg/ml ampicillin and incubated at 37 °C at 150 rpm for 16-18 hours. The clones from the respective inocula (*E. coli* BL21 (DE3)-pHyal_sk and BL21 (DE3)- pHyal_sk_SL), were separately grown in the fermenter on a minimum culture medium whose composition per liter was given by: 2 g Na₂HPO₄*2H₂O, 2 g KH₂PO₄, 4 g K₂HPO₄, 3.8 g citric acid, 3.3 g (NH₄)₂SO₄, 0.6 ml PPG 2000 antifoam (Fluka Code 81380). The pH was corrected after sterilization at 121 °C to 6.8 with a 25% solution of ammonium hydroxide % (SIGMA), and only after having added the following components per liter of medium, sterilized by filtration through 0.2µm filters: 0.49g MgSO₄*7H₂O, 0.0147g CaCl₂, 1ml FeCl₂ (0.2M), 2ml trace elements (trace elements per liter: 0.96g citric acid, 0.25g CoCl₂*6H₂O, 1.5g MnCl₂*4H₂O, 0.15g CuCl₂*2H₂O, 1.5g H₃BO₃, 0.25g Na₂MoO₄*2H₂O, 1.3g Zn(CH₃COO)₂*2H₂O), 0.01g thiamine, 5g glucose, 3g yeast extract.

A solution of glycerol (~1.2 kg per 10L fermentation) sterilized in an autoclave was given as a feed and the following components, previously filtered with 0.2 µm filters, were then added per liter of feed: 2 g Na₂HPO₄*2H₂O, 3 g KH₂PO₄, 5.4 g K₂HPO₄, 3.8 g citric acid, 4 g (NH₄)₂SO₄, 9 g MgSO₄*7H₂O, 0.047 g CaCl₂, 1 ml FeCl₂ (solution 0.2M), 2 ml trace elements (trace elements per

liter: 0.96 g citric acid, 0.25 g $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$, 1.5 g $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$, 0.15 g $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$, 1.5 g H_3BO_3 , 0.25 g $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$, 1.3 g $\text{Zn}(\text{CH}_3\text{COO})_2 \cdot 2\text{H}_2\text{O}$ and 0.01g thiamine. The feed is given 6 hours after inoculation until the nineteenth hour with an exponential ratio of addition. The choice to use glycerol as a carbon source is due to the fact that the expression cells of *E. coli* used generate acetic acid (acetate) as an undesired by-product that has numerous adverse effects on the production of recombinant proteins [14]. In particular, the cells of *E. coli* produce acetic acid as an extracellular co-product of the aerobic fermentation, the rate of formation of acetate is directly related to the rate at which the cells grow or to the rate at which they consume the solid substrate as a carbon source, glucose. In common fed-batch fermentation systems, the growth rate of the culture is determined by the speed of feeding of the "glucose" limiting nutrient resulting in cell growth above the threshold which leads to a consequent production of acetate and thus to a reduction of expression of recombinant proteins.

In this invention, various strategies have been developed to limit the accumulation of acetate in order to reduce the negative effects and increase the productivity of the recombinant protein. A strategy that has allowed us to obtain excellent results was to use glycerol as a carbon source. Glycerol, unlike glucose, is not fermented to acetic acid. The results obtained showed that the use of glycerol, rather than glucose, in the fed-batch fermentation process developed in this invention has improved the yield of the soluble recombinant protein

hyaluronidase of about 2 - 3 times [15]. Moreover, unlike glucose which has an inhibitory effect on the promoter that regulates the synthesis of the recombinant protein of this invention, the glycerol can be given to fermentation also after induction with IPTG, allowing the reduction not only of the formation of acetate but also the increase of the soluble formation of recombinant hyaluronidase. Furthermore, the low cost of glycerol compared with glucose makes it preferential as a carbon source for the fermentation of *E. coli*, in the industrial field.

After induction with Isopropyl β -D-1-thiogalactopyranoside (IPTG), 1mM final solution, the feed is administered to the culture every hour and in the same amount as the last addition for 5 hours. The induction started 24 hours after inoculation and continued for 12 hours. The fermentation parameters developed are as follows: temperature 37 °C, agitation 600rpm, air flow 5-10 liters air per minute and head pressure of about 0.8 bar.

The bacterial cells are harvested after the induction period of 12 hours by centrifugation at 7500 rpm for 25 minutes. After collection, the bacterial cells are stored at -80 °C, ready to be used for the extraction and purification of the recombinant hyaluronidase. The recombinant protein expressed by *E. coli*, in the different fermentation parameters, is analyzed by electrophoresis run in SDS-PAGE (12%) after staining with Coomassie Brilliant Blue G-250 (BIO-RAD, 161-0406), while the enzyme activity is analyzed by turbidimetric assay [16].

The cells of *E.coli* BL21 (DE3) transformed with the vector pHyal_sk are induced to express the soluble heterologous protein in the periplasm, in the fermenter with 10L of medium. In SDS-PAGE, the recombinant expressed had a molecular weight of about 24 kDa and an amount of protein expressed in the periplasm of about 0.4 g/L of culture, the maximum quantity reached after 6 hours of induction with 1mM IPTG at 37 °C (Figure 14).

The cells of *E.coli* BL21 (DE3) transformed with the vector pHyal_sk_SL are induced to express the soluble heterologous protein in the periplasm, in the fermenter with 10L of medium. The periplasmic soluble portion turned out to be present at a concentration of about 1.2 g/L culture, with an enzymatic activity greater than 48000U/ml culture. In SDS-PAGE, the recombinant expressed had a molecular weight of about 24 kDa, constituting about 16-18% of the total bacterial proteins, after induction with 1mM IPTG at the twelfth hour at 37 °C (Figure 15).

Example 15: Fedbatch fermentation of *E.coli* BL21 (DE3) transformed with the vector pHyal_sk_SL on 20L medium.

Briefly, the cells of *E.coli* BL21 (DE3) transformed with the vector pHyal_sk_SL are induced to express the soluble heterologous protein in the periplasm, in the fermenter with 20L of medium. The periplasmic soluble portion was found to be present at a concentration of about 2g/L of culture (Table 2) with an enzymatic activity greater than 87000U/ml culture (7.5×10^7 - 8 , 7×10^7 IU/l of culture), approximately 670-750 times higher compared to the autologous hyaluronidase produced in the fermenter as

described in the above patent [9]. In SDS-PAGE, the expressed recombinant had a molecular weight of about 24 kDa, constituting about 16-18% of the total bacterial proteins, after induction with 1mM IPTG at the twelfth hour at 37 °C.

The stability of the plasmid during the fermentation phase, for all clones tested with the fed-batch method, was 100% (Table 2). The stability of the plasmid is monitored until the end of the fermentation by screening with the replica plating technique [29] which allows replication of the colonies on plates containing the antibiotic.

Finally, clones genetically engineered in a different way, were tested for their capacity to produce, in the fermenter, the recombinant hyaluronidase encoded by the gene isolated according to this invention. The results are summarised in Table 1.

Example 16: Analysis of recombinant hyaluronidase activity in the fermentation broth

From 0.1 ml of culture from specific induction times or from the final product, the pellet was obtained after centrifugation at 7500 RPM centrifuge (Eppendorf centrifuge 5402, rotor F-45-18-11) for 10 minutes. The cell pellet was resuspended in 500µl of B-PER Bacterial Protein Extraction Reagent (PIERCE) and mixed by vortexing (Heidolph Reax top) at maximum speed for about 1 minute or until complete resuspension of the pellet. The suitably resuspended pellet was centrifuged at 13000 RPM for 10 minutes to separate the soluble proteins from insoluble proteins. The collected supernatant (soluble

proteins) was tested for the presence of hyaluronidase activity using the turbidimetric method described by Di Ferrante [16] modified for analysis on 96-well plates. Briefly, for single well, 31 μ l of incubation buffer [17], 8 μ l of BSA (0.2 mg/ml), 8 μ l of hyaluronic acid (2mg/ml), 13 μ l of H₂O and 10 μ l of the supernatant (soluble proteins) diluted 10, 100 and 1000 times with 1x PBS (Sigma-P4417), were set up. The plate is incubated at 37 °C for an hour. After one hour of incubation, 200 μ l of CTAB alkaline solution (2.5% (w/v) in 0.5 M NaOH) were added to each well to precipitate the undigested hyaluronic acid and the plate is incubated for 20 minutes at room temperature. The extent of precipitation was measured at an optical density of 640nm.

Subsequently, the activity per ml of recombinant protein in the culture broth was obtained using the following calculation: activity of ml obtained from the test/2 x dilution factor x 10 = activity on ml of product from fermentation.

A Hyaluronidase standard (FIP) was used to construct a standard curve and the activity of the recombinant hyaluronidase in the periplasmic portion was calculated using this curve.

Example 17: Large-scale extraction of the soluble fraction

From pellet stored at -80°C (deriving from the fermentation of E.coli BL21(DE3) transformed with the pHyal_sk_SL vector) an amount equivalent to 0.6 liters of fermentation product (approximately equivalent to the range of 80-90g cell pellet, reflecting approximately a production of 1-1.2 g/L recombinant hyalurodinase) is

placed to equilibrate for 45 minutes at room temperature. First method: Once equilibrated, the pellet was treated with 210 ml fresh solution (5°C) for the dispersion of pellet (205.2g/L glucose, 5.6g/L EDTA). The pellet is resuspended, with the dispersion solution, under magnetic stirring for 15 minutes at room temperature and subsequently for about 1 hour at 5°C, using a magnetic stirrer Heidolph type MR2002 at a speed of 500rpm. After about 1 hour the resuspended pellet is added cold in a 4.5L solution for osmotic shock (1.2g/L TRIS, 4ml/L HCl 2N, 0.1g/L MgCl₂) for the extraction of the periplasmic protein. The mixture obtained is stirred for 4 hours at 4°C, using a magnetic stirrer Heidolph type MR2002 at a speed of 500rpm.

After the osmotic shock step, the product obtained containing the dispersed E.coli cells was centrifuged at 5°C for 45 minutes at speeds of about 7500rpm using a Sorval Evolution Rc centrifuge with SLC-6000 rotor. After centrifugation, the supernatant is collected while the pellet is eliminated. At this point, the supernatant was homogenized using the "Ultra Turrax" system with speed level 2 for 15 seconds.

The supernatant, after treatment with "Ultra Turrax", was brought to pH 8 and filtered by gravity with 0.65µm filters. After filtration, the concentration of Tris in the filtrate was brought from 10mM to 50mM with a 3M Tris-HCl solution and later brought to pH 8. The concentration of the extracted hyaluronidase was assessed in SDS-PAGE and found to be of about 750-850mg/total (22-24% of total periplasmatic proteins). The activity of the extracted recombinant hyaluronidase is instead assessed

by Dorfman's turbidimetric method.

Second method: Once equilibrated, the pellet was treated with the 500 ml B-PER Bacterial Protein Extraction Reagent (PIERCE) solution for the release of the periplasmic proteins in the medium. The pellet is resuspended, with the B-PER solution, under magnetic stirring for 30 minutes at room temperature and subsequently for further 30 minutes at 5°C, using a magnetic stirrer Heidolph type MR2002 at a speed of 1000rpm. After about 1 hour the resuspended pellet is centrifuged at 5°C for 45 minutes at a speed of about 11,000rpm using a Sorval Rc-5B centrifuge with Sorvall rotor. After centrifugation, the resulting supernatant was added cold in a 5L 50mM Tris-HCl solution, pH 8. The solution obtained is stirred for 10 minutes at 4°C, using a magnetic stirrer Heidolph type MR2002 at a speed of 200rpm. After stirring, the solution was homogenized using the "Ultra Turrax" system with speed level 2 for 15 seconds. The supernatant, after treatment with "Ultra Turrax", was brought to pH 8 and filtered by gravity with 0.65µm filters. The concentration of the extracted hyaluronidase was assessed in SDS-PAGE and found to be of about 0.9-1.1g/total (16%-18% of total periplasmic proteins). The activity of the extracted recombinant hyaluronidase is instead assessed by Dorfman's turbidimetric method.

Example 18: Recombinant purification

The resins and the chromatographic columns were purchased from GE Healthcare Life Sciences and maintained according to the manufacturer's specifications. The balance and elution steps were carried out with a Fast Performance

Liquid Chromatography (FPLC; AKTA explorer 100, GE Healthcare) system at a flow of 40-50ml/min for all 3 chromatographies. At the end of each chromatographic step the hyaluronidase activity was controlled with the modified Dorfman's assay described [9]. Once the soluble fraction is extracted from the periplasmic portion, it is loaded on the first strong ion-exchange chromatography.

Strong ion-exchange chromatography (Q sepharose XL):

The filtered extract brought to 50mM Tris-HCl and pH 8 was loaded on 500ml-600ml Q sepharose XL resin (GE Healthcare) packed in a XK-50 (GE Healthcare) column and equilibrated with 8 bed volumes (BVs) of Tris-HCl buffer at pH 8. After loading, the column was washed, first with 3 BVs of the same buffer and subsequently with 8 BVs of Tris-HCl buffer at pH 8 with 40mM NaCl, then the bound proteins were eluted with 5 BVs of a Tris-HCl buffer solution at pH 8 with 110mM NaCl. The eluted proteins were collected in a single fraction having a volume of about 950 ml and subjected to hyaluronidase activity assay.

Diafiltration and weak ion-exchange chromatography (CM-Sepharose® Fast Flow):

The fraction obtained is concentrated to 100ml using the tangential ultrafiltration Labscale TFF System (Millipore) and using Polyethersulfone (PES) filters with cut-off comprised between 3 and 8kDa, preferably of 5kDa. After concentration, the sample is diluted 10 times with 50mM sodium acetate buffer at pH 4. The fraction thus obtained was loaded on 300ml-400ml CM-Sepharose® Fast Flow resin (GE Healthcare), packed on a XK-50 column (GE Healthcare) and equilibrated with 6 bed volumes (BVs) of

50mM sodium acetate buffer at pH 4.0. After loading (preferably at a temperature of 4-5°C), the column was washed with 3 BVs of the same buffer, then the bound proteins were eluted with 8 BVs of a 50mM sodium acetate buffer solution at pH 4.5. The eluted proteins were collected in a single fraction having a volume of about 380 ml and subjected to hyaluronidase activity assay.

Diafiltration and aromatic hydrophobic interaction chromatography (Phenyl-Sepharose HP).

The fraction obtained and positive to the enzymatic dosage is concentrated to 100ml using the tangential ultrafiltration Labscale TFF System (Millipore) and using Polyethersulfone (PES) filters with cut-off comprised between 3 and 8kDa, preferably of 5kDa. After concentration, the sample is diluted 10 times with 50mM sodium phosphate buffer with 1.5M ammonium sulphate, pH 7. The fraction thus obtained was loaded on 300ml-400ml Phenyl-Sepharose HP resin (GE Healthcare), packed on a XK-50 column (GE Healthcare) and balanced with 8 bed volumes (BVs) of 50mM sodium phosphate buffer with 1.5M ammonium sulphate, pH 7. After loading, the column was washed with 3 BVs of the same buffer, then the bound proteins were eluted with 5 BVs of a 50mM sodium phosphate buffer solution with 0.8M ammonium sulphate, pH 7. The eluted proteins were collected in a single fraction having a volume of about 730 ml and subjected to hyaluronidase activity assay. After the enzymatic activity assay, the eluted fraction was subjected to ultrafiltration and dialysis with 10 volume 1x PBS (SIGMA-P4417), using Polyethersulfone (PES) filters with cut-off comprised between 3 and 8kDa, preferably of 5kDa,

brought to a concentration of about 1mg/ml and filtered with 0.2 μ m filters (protein concentration is determined by BCA Protein Assay Reagent Kit, PIERCE). During the purification steps to obtain a good recovery of the purified product, the recombinant portion is loaded on the chromatographic columns with a maximum ratio of 1.5mg hyaluronidase per ml of resin. All the eluted protein fractions, both those enzymatically active and those inactive or poorly active, were then analyzed by SDS-PAGE at 12% and then stained with silver stain according to the manufacturer's instructions; in all the fractions having hyaluronidase activity there was a marked protein band of about 24kDa (Fig. 16). In the different steps of purification, the protein concentration of the recombinant portion was estimated as previously described in SDS-PAGE(12%) and found to be of total 0.45-0.5g/L in the first chromatography (Q sepharose XL), total 0.45-0.50g/L in the second chromatography (CM-Sepharose® Fast Flow), total 0.4-0.45g/L in the third chromatography (Phenyl-Sepharose HP) and total 0.35-0.4g/L after DIA-filtration. At the end of the purification process applied on about 1L of fermentation product, about 600-650mg (Enzymatic activity greater than 2.6x10⁷U/L purified fermentation product) of recombinant hyaluronidase (Table 3) were obtained.

Example 19: Analysis and characterization

Determination of hyaluronidase activity

The hyaluronidase activity was measured with the modified Dorfman's method [10]. Briefly, the product obtained by the different steps of the process was diluted in 0.03M phosphate buffer, 0.82% NaCl, pH 6.3 and 1ml of the thus

obtained solution was mixed with 1ml substrate buffer (0.03M phosphate buffer, NaCl 10.82%, pH 6.3) containing 0.5mg hyaluronic acid. The enzymatic digestion was carried out at 37°C for 30 minutes and at the end of the incubation process, turbidity was generated by adding a 4ml horse serum-based acidic solution (SIGMA). The optical density at 640 nm was measured exactly 30 minutes after the addition of the horse serum acidic solution. A standard of hyaluronidase from mammal testicles (EDQM, FIP Hyaluronidase, H1115000) containing 328 IU/mg was used to construct a standard curve and the activity (in units) of the samples was calculated using this curve.

SDS-PAGE electrophoresis

The electrophoretic assays on polyacrylamide gel in the presence of sodium dodecyl sulfate (SDS-PAGE) were carried out using Laemmli's method [11] on 12% polyacrylamide gel, using a Mini-PROTEAN 3 (BIO-RAD) according to the manufacturer's instructions. The concentration and the molecular weight of the hyaluronidase in the fermentation product and in different purification steps were estimated by comparison with standard low molecular weight proteins (GE Healthcare).

The polyacrylamide gels suitably stained with Coomassie (BIO_RAD) after the electrophoretic run, were acquired by a laboratory image capturing device ImageQuant™ 300 TL (GE Healthcare), while (quantitative and qualitative) assays were performed using the image analysis software ImageQuant TL (GE Healthcare).

N-terminal end sequencing

The N-terminal amino acid sequencing was carried out

according to Edman's degradation method using an automated protein sequencer in pulsed liquid phase (ABI-Perkin Elmer Mod. 477A). BLAST software [18] was used to conduct homology research in the GenBank database and in that of the human genome project of the Streptomyces species available on the web. The fractions, obtained by the purifications of the E.coli strain transformed with the pHyal_sk vector and the E.coli strain transformed with the pHyal_sk_SL vector according to the invention, were subjected to SDS-PAGE electrophoresis on 12% gel, as described above, then to blotting on polyvinylidene difluoride membrane (BIO-RAD) and stained according to the manufacturer's instructions. The band relating to hyaluronidase for both productions was separated with a scalpel, trying to obtain a piece as small-sized as possible (3mm x 10mm) and was loaded in the reaction chamber of the sequencer.

The sequencing of the N-terminal end, conducted as described hereinbefore, allows to determine that the two recombinant hyaluronidases produced and coming from two used different genetic engineering and expression systems, contain differences in the N-terminal amino acid sequence. In case of E.coli sample transformed with the pHyal_sk_SL vector according to the invention, the assay provided chromatograms in which a single N-terminal amino acid sequence was significantly present, allowing to reconstruct the test sequence reported hereinafter: AGENGA (SEQ ID NO: 42). The above-mentioned experimentally determined sequence corresponds to the N-terminus of the protein isolated in its autologous form described by [9] free from methionine at position 1.

In case of the E.coli sample transformed with the pHyal_sk vector according to the invention, the assay instead detected the presence of at least two N-terminal amino acid sequences, reported hereinafter is the listing of the N-terminal amino acids detected by the sequencing: Most represented sequence MAGENGA (SEQ ID NO: 43) which corresponds to the N-terminus of the mature protein with methionine at position 1, and a less represented sequence AQPAMAMAGENGA (SEQ ID NO: 44) which corresponds to the partially mature protein (contains sequence AQPAMAM (SEQ ID NO: 45) belonging to the signal peptide apparently not totally deprived of the protein by the cell system).

Comparison of hyaluronidase activity between the heterologous and autologous form.

The enzymatic potential of the hyaluronidase according to the invention (E.coli transformed with the pHyal_sk_SL vector) was assessed by comparison with the enzymatic activity of the autologous hyaluronidase [9], using the enzymatic assay described [9] and the activity value is reported to be in both cases greater than 4×10^4 IU/mg (the protein concentration was determined by BCA Protein Assay Reagent Kit, PIERCE).

The result of this assay shows that hyaluronidase according to the invention, in particular of the form coming from the E.coli strain engineered with the pHyal_sk_SL plasmid, has the same activity as the autologous form. However, by means of the production and purification methods described in the invention it was possible to accurately assess the value of the enzymatic activity of the recombinant hyaluronidase according to the invention, which was found to be greater than

40,000U/mg protein.

UV spectra analysis and comparison of spectra of circular Dichroism of the heterologous and the autologous forms.

Circular dichroism (CD) experiments: Spectra at the Far-UV circular dichroism were collected at room temperature on a Jasco spectropolarimeter J-715 model, with quartz cell having path length of 1 millimeter. Other test settings were: scan speed, 10nm/min, sensitivity, 50 MDEG, time constant, 16s, bandwidth, 3nm. The circular dichroism measurements were conducted on protein solutions (autologous hyaluronidase, recombinant hyaluronidase according to the invention) at concentration of $2 \cdot 10^{-6}$ M. All the samples were diluted at a final concentration of $2 \cdot 10^{-6}$ M using ultra-pure water. The CD spectra were collected at 260-195nm blank corrected and adjusted for dilution.

The circular dichroism spectra are reported in Figure 17. The overlay files match: the lower line corresponds to the autologous hyaluronidase [9] and the upper one corresponds to the heterologous hyaluronidase according to the invention. The two spectra have a superposable profile, confirming the same structure for both the samples (Fig. 17-a). The small difference which is noted may be attributed to the not perfect coincidence of the concentrations of the two solutions.

From the UV spectra, the recombinant hyaluronidase sample does not show aggregation. From this study it may be inferred that the preparation according to the invention has a secondary structure very similar to that of the autologous hyaluronidase [9] and that the protein produced according to the present invention does not show

aggregation (Fig. 17-b).

Mass spectrometry

The mass spectrometry assays for determining the molecular weight were conducted using Quattro micro mass spectrometer (Waters), while the assay of peptide mapping to confirm the identity of the primary structure of the recombinant portion was carried out using the accurate mass values of the peptides determined by means of the MALDI-MS Voyager DE-PRO system (Applied Biosystems, Framingham MA, USA) after separation in RP-HPLC.

The fraction obtained after purification of recombinant hyaluronidase according to the invention was subjected to digestion with trypsin, after separation in RP-HPLC, the peptide mixture produced for each sample was analyzed by MALDI-MS in reflector mode. The study and interpretation of the MALDI spectra acquired therefore respectively allowed verifying 97% identity of the primary structure of the reference amino acid sequence [9] and over 94% identity of the primary structure of the theoretical amino acid sequence according to the invention (peptide sequence predicted by <http://web.expasy.org/translate/>) with the amino acid sequence of the sample produced according to the invention (SEQ ID NO: 21).

Furthermore, the fraction obtained after purification of the recombinant hyaluronidase according to the invention was subjected to determination of molecular weight of the protein by means of mass spectrometry and the result of the assay is reported in Figure 18.

Isoelectric focusing

The protein fraction to be analyzed (recombinant

hyaluronidase obtained according to the invention) is mixed in a suitable loading buffer and loaded onto IPG strips at pH 3-10 (ReadyStrips 7cm, BIO-RAD); incubation is performed at 25°C until absorption of the sample and the strip is loaded onto the PROTEAN IEF Cell (BIO-RAD) for isoelectric focusing (IEF). At the end of the isoelectric focusing run the strip is stained with IEF Gel Staining solution (BIO-RAD) for 45 minutes and then destained with Destain solution (BIO-RAD). The destained IPG strips were acquired by a laboratory image capturing device ImageQuant 300 TL (GE Healthcare) while (quantitative and qualitative) assays were performed using the image analysis software ImageQuant TL (GE Healthcare).

The isoelectric point of the sample was determined by comparison with the isoelectric points of the reference standards (IEF Marker pH 3-10, SERVA). The result of the assay is reported in Figure 19.

Characterization by capillary electrophoresis of the recombinant hyaluronidase and determination of the molar extinction coefficient.

The qualitative-quantitative assay of the protein fraction to be analyzed (recombinant hyaluronidase obtained according to the invention) was performed by BIOTEKNET (Napoli, Italy) by means of capillary electrophoresis with a P/ACE MDQ Beckman-Coulter instrument equipped with diode-array detector and UV lamp, using a capillary of fused silica (50cm actual length, 60.2cm total length, 50µm inner diameter) and a 20mM sodium citrate buffer, at pH 2.5, applying an e.p.d. of 25kV (ensuring a greater stability in the

electrophoretic separation process and of the current used) for 15 min and detecting the absorption at 200nm. Before proceeding with the sample assay, the BSA (bovine serum albumin) was suitably analyzed at three different concentrations (1mg/mL; 0.8mg/mL; 0.4mg/mL), using the above-mentioned method and thereby obtaining a calibration straight line. The assay was carried out on the same sample twice diluted (Fig. 20). In both electropherograms it is possible to identify the presence of a single peak (Purity 100%) having migration time of 7.7 ± 0.9 min and the protein quantification, although affected by a calibration with external standard (BSA), therefore not with the same protein, returns a high purity, and a quantification superimposable to the expected one (~1mg/ml). The research work on the determination of the molar extinction coefficient of the recombinant hyaluronidase may be divided into four experimental moments: 1. Densitometric assay of the hyaluronidase samples of the invention, 2. Spectrophotometric assay of the hyaluronidase samples of the invention, 3. Identification of theoretical absorbance, 4. Identification of the molar extinction coefficient.

At this point, once collected the information in the preceding steps, the Beer-Lambert law is applied: $A = \epsilon \cdot l \cdot C$ where ϵ is referred to as molar absorption coefficient, C is the molar concentration of the solution and l is the optical path. Based on this formula and on our obtained information, the molar absorption coefficient, at a wavelength of 280nm, is as follows:

12383	L*mol ⁻¹ *cm ⁻¹	Abs	0.1%(=1g/L)	0.570	(Molar
-------	---------------------------------------	-----	-------------	-------	--------

extinction coefficient of hyaluronidase produced according to the present invention).

HPLC assay by means of gel filtration

For the assays by means of gel filtration the LC-10AD HPLC instrument (SHIMADZU) was used with a Bio-Sil SEC column (BIO-RAD), eluting with 0.05M NaH₂PO₄, 0.05M Na₂HPO₄, 0.15M NaCl, pH 6.6, at 1ml/min. The absorption wavelength used was 214nm (SPD-10A, SHIMADZU). The purity of the protein was determined using the software LC solution 1:21 SP1. The fraction obtained after purification of recombinant hyaluronidase as described in the invention was subjected to gel filtration column HPLC as described above. The result of the assay on purity of the recombinant portion is reported by the chromatogram in Figure 21-a and is of 100%.

Determination of the level of purity by means of RP-HPLC. For the purity assays by means of Reversed-Phase HPLC the LC-10AD HPLC instrument (SHIMADZU) was used with a Vydac 214ATP54 C4 (Grace Davison Discovery Sciences) column, eluting with 50mM Tris pH 7.5 with 1-propanol, at 0.5ml/min. The absorption wavelength used was 220 nm (SPD-10A, SHIMADZU). The purity of the protein was determined using the software LC solution 1:21 SP1. The fraction obtained after purification of the recombinant hyaluronidase as described by the invention was subjected to RP-HPLC on a (reversed) hydrophobic-phase column as described above. The result of the assay on purity of the recombinant portion is reported by the chromatogram in Figure 21-b and is very close to 100%.

Characterization of the bacterial recombinant hyaluronidase by means of electrophoresis on

polyacrylamide gel.

The electrophoretic assays on polyacrylamide gel in the presence of sodium dodecyl sulfate (SDS-PAGE) were carried out using Laemmli's method [11] on 12% polyacrylamide gel, using a Mini-PROTEAN 3 (BIO-RAD) according to the manufacturer's instructions. The concentration and the molecular weight of the hyaluronidase in the fermentation product and in different purification steps were estimated by comparison with standard low molecular weight proteins (GE Healthcare).

The polyacrylamide gels, suitably stained with Coomassie (BIO_RAD) after the electrophoretic run, were acquired by a laboratory image capturing device ImageQuant 300 TL (GE Healthcare), while (quantitative and qualitative) assays were performed using the image analysis software ImageQuant TL (GE Healthcare).

On the other hand, for the Western Blot assay, the proteins were fractioned in SDS-PAGE at 12% and transferred to nitrocellulose membranes. The proteins of interest were then identified by incubation with a 1:2000 dilution of anti-hyaluronidase antibody (Abnova) in 10% dry milk/PBS for 12 hours, and the specific reaction was highlighted by means of the addition for 1 hour of mouse anti-IgGs secondary antibodies conjugated with alkaline phosphatase, followed by detection with the BCIP/NBT substrate (BUF045A, SEROTEC).

The production of recombinant hyaluronidase according to the invention from E.coli BL21(DE3) engineered cells and therefore without the presence of animal derivatives allowed producing the protein with a high specific

enzymatic activity (>40000 Units/mg of protein). The recombinant protein produced according to the invention had a level of purity 100 times higher than that of the hyaluronidase standard from mammal testicles (EDQM, FIP Hyaluronidase, H1115000) as shown in Figure 22. While recombinant hyaluronidase purified according to the invention after migration on 12% SDS-PAGE gel and GelMate Blue (EuroClone) coomassie staining had a single band, the bovine hyaluronidase, available on the market, showed several impurities. A smaller band (at about 75-80kDa) in the smear of proteins of the bovine hyaluronidase reacted with an anti-hyaluronidase polyclonal antibody (Abnova) by Western Blotting, confirming that enzyme hyaluronidase is a smaller component of hyaluronidase preparations derived from animals (Fig. 22).

Endotoxin detection

The Limulus Amebocyte Lysate Test (LAL), which uses the reagent prepared from blood of limulus Poliphemus, showed to be the most sensitive and specific test to detect and measure the level of bacterial endotoxins in raw materials used in the production and for the "in-process" monitoring of endotoxin levels. Endotoxins, more commonly known as pyrogens, cause from fever to irreversible shock, from difficulties in blood and tissue exchanges to lethal consequences.

With the recombinant hyaluronidase being produced according to the invention in E.coli cells, it was essential to assess the level of endotoxins in the final product. To this end, we used the method of "Chromo-LAL", a kinetic chromogenic test for the quantitative detection of endotoxins produced by Gram-negative bacteria.

Briefly, in the "Chromo LAL (art 32427, PBI S.p.A - Italy)" test, the lysate and the chromogenic reagent substrate co-freeze-dried were mixed with the hyaluronidase sample (produced according to the invention) in a multiwell micro-plate (96 wells) and incubated at $37\pm 1^{\circ}\text{C}$ in a suitable reader (ELX 808 IU, BioTek). The absorbance values read were collected and analyzed by a dedicated software. The time required for hyaluronidase sample to reach a specific absorbance value (optical density) was calculated. Furthermore, a standard calibration curve (CSE, lot.104, art.17078, PBI S.p.A - Italy) was built which shows the linear correlation between the "start time" log and the log of standard endotoxin concentration. The maximum range between the endotoxin concentrations of the standard curve is 0.005EU/ml-50EU/ml. The sensitivity [19] of the test was defined from the lowest concentration of endotoxin used to build the standard curve. The maximum sensitivity of this test is 0.005EU/ml.

The endotoxin concentration for the corresponding "start time" of the hyaluronidase sample was read from the standard curve which is a log-log diagram deriving from the scores obtained calculating the "start times" versus standard concentrations.

At the end, the estimated value of endotoxins in the hyaluronidase sample produced according to the invention was calculated by the Gen5 software (BioTek) resulting to be very low, that is lower than 0.5 endotoxin units per milligram of recombinant hyaluronidase (Table 4).

Determination of proteins and DNA deriving from host cells.

As regards the determination of proteins deriving from E.coli host cells used for the heterologous expression of recombinant hyaluronidase (as described by the present invention) the ELISA method was used, in particular, the Enzyme Immuno Assay kit "E.coli HCP" from Cygnus technologies (F010). The assay is based on the sandwiched use of affinity-purified antibodies directed to a mixture of 6 E.coli strains commonly used for cloning and expression of recombinant proteins.

The test was performed according to the manufacturer's instructions, on the purified sample of recombinant hyaluronidase, the concentration of proteins deriving from E.coli (host strain) is directly proportional to the development of color caused by enzymatic reaction of alkaline phosphatase conjugated to the antibody.

The concentration of proteins deriving from the host strain towards the standard concentrations was estimated (calculation and calibration of the curve were performed by the GEN 5 software, BioTek) in the sample of hyaluronidase produced according to the invention to be lower than 10ppm as shown in Table 4 (the limit approved by the competent authorities is below 100ppm).

On the other hand, the determination of the quantity of DNA from the host strain of E.coli was carried out in the sample of recombinant hyaluronidase (produced according to the invention), using the DNA Threshold method.

This assay was performed at the Charles River Biopharmaceutical services GmbH laboratories, Germany. The studies indicated with the code M1/F07/12 and M2/F07/12 gave as a final result a very low level of DNA deriving from the cell host, calculated to be lower than

20pg (the limit approved by the competent authorities is lower than or equal to 300pg/mg of protein) per milligram of recombinant hyaluronidase (Table 4).

Example 20: Assay on agarose gel of hyaluronic acid depolymerization

For the in vitro assessment of the capability of recombinant hyaluronidase, produced according to the invention, of depolymerizing hyaluronic acid (Hyalgan®; Fidia S.p.A., Italy) in its primary constituents N-acetylglucosamine and glucuronic acid, the electrophoretic assay method in agarose gel [20] was used after hyaluronic acid is digested with 1 unit of recombinant hyaluronidase within the indicated times from 5 minutes to 24 hours.

Briefly, the hyaluronic acid samples (500kD-730kD), after reacting with recombinant hyaluronidase within the indicated times (from 5 minutes to 24 hours) were separated using the Sub-CellGT electrophoresis system (BIO-RAD) and gels with 1% agarose (25cm in length). The samples were migrated in electrophoresis for about 12 hours at a temperature of about 16°C with a constant voltage of 50 Volts. Staining is carried out as described in previous studies [20].

The results shown in Figure 23 indicated that the recombinant hyaluronidase, produced according to the invention, is capable of completely digesting the substrate until reaching undetectable levels of hyaluronic acid before 24 hours.

Example 21: Stability against proteolytic enzymes

Hyaluronidase is an enzyme hydrolyzing hyaluronic acid,

therefore increasing the permeability of connective tissue enhancing the diffusion and dispersion of the drug, that is administered locally subcutaneously, in the surrounding tissues.

In some treatments, hyaluronidase is administered in low doses (the typical dose used is 15 units), to reduce the damages caused by the leakage of antibiotics, hyperosmotic solutions, acid or basic solutions, or the correction of hyaluronic acid-based fillers to avoid allergic and anaphylactic reactions. Therefore, it is fundamental for the hyaluronidase to be stable at these doses towards the proteolytic enzymes present in connective tissue, which may easily degrade it once injected, inhibiting its action. In order to test and compare the resistance of recombinant hyaluronidase with respect to the bovine one currently used in the market, against proteolytic enzymes, a turbidimetric model for *in vitro* assays was provided. Briefly, recombinant hyaluronidase (prepared according to the invention) at the concentration of 10U (<250ng) and the bovine hyaluronidase 100U (300µg) were treated separately with two different doses of Pronase E (200µg and 500µg) in a phosphate buffer solution (pH 7.0) at 37°C for 1 hour, 24 hours and 48 hours. The residual enzymatic activity (expressed as percentage) of the two concentrations of enzymes treated and not treated with Pronase E was measured according to Dorfman's method as described in the patent. The results obtained are placed in a diagram and shown in Figure 24.

Example 22: Effect of human and animal serum on hyaluronidase activity

In this invention, thanks to the provision of an in vitro test model using the turbidimetric model, what had already emerged from previous clinical studies was confirmed, that is, enzymatic activity of bovine hyaluronidase (bovine PH20) is inhibited by human and/or animal blood, but it was however found that human and/or animal blood does not inhibit hyaluronidase from recombinant *S.koganeiensis* (Fig. 25). The method used to assess, in this invention, inhibition of hyaluronidase activity by (animal/human) blood was previously described by Albert DORFMAN, et al [21]. Briefly, the two concentrations of recombinant hyaluronidase produced according to the invention (40 units, 400 units), and bovine hyaluronidase (40 units, 400 units), were separately and respectively treated with serum coming from animal blood and serum coming from human blood in a sulphate buffer solution (pH 7.0) mixed with substrate buffer containing 0.5 mg hyaluronic acid. The mixture thus obtained was placed at 37°C for 30 minutes, 1 hour and 6 hours. The relative enzymatic activity of the two concentrations of enzymes treated with the sera was measured at the end of each established time interval after having generated turbidity by adding a 4ml horse serum-based acid solution and continuing as per the Dorfman's method previously described. The development of turbidity due to the addition of the serum was corrected by the blank containing all the reagents, except for hyaluronidase.

Therefore, these latter studies show that the recombinant hyaluronidase produced according to the invention, which has a high hyaluronidase activity and high stability

versus proteolytic enzymes, is capable of performing, with its maximum bioavailability, the total activity in bloodstream without the possibility of detecting bacterial or viral infections, proving to be effective also for cardio- and cerebro-vascular therapies.

Bibliographic references

- [1] L.H. Bookbinder, et al, Journal of Control Release. 2006 Aug 28;114(2):230-41. Epub 2006 Jun 7.
- [2] Bratisl Lek Listy 2009; 110(1).
- [3] US 2008/0124316 A1.
- [4] Acta Med Scand. 1984;216(2):209-13.
- [5] Dorfman A, Ott ML, Whitney R: The hyaluronidase inhibitor of human blood. J Biol Chem 174: 621, 1948.
- [6] McClean D: The in-vivo decapsulation of streptococci by hyaluronidase. J Pathol Bacteriol 54: 284, 1942.
- [7] US 2011/0053247 A1.
- [8] US 4,258,134.
- [9] WO 2010/130810 A1.
- [10] Dorfman A. 1955.
- [11] Laemmli, U.K. 1970.
- [12] Sambrook J, Russel DW (2001).
- [13] Peter B. Kaufman, William Wu, Donghern Kim, Leland Cseke 1995; Sambrook and Russell (2001).
- [14] Sørensen, H.P. and Mortensen, K.K. (2005). Advanced strategies for recombinant protein expression in *Escherichia coli*. J. Biotechnol. 115, 113-128.
- [15] Luo, Q. et al. (2006) Optimization of culture on the overproduction of TRAIL in high-cell-density culture by recombinant *Escherichia coli*. Appl. Microbiol. Biotechnol. 71, 184-191.
- [16] Di Ferrante 1956.

- [17] McIlvaine's buffer, McIlvaine 1921.
- [18] Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* 25:3389-3402.
- [19] Ebner, C., D.Kraft, F. Prasch, R. Steiner, and H. Ebner. Type 1 allergy induced by LYMULUS Amebocyte Lysate (LAL). *Clinical and Experimental Allergy* 22:417-419 (1992).
- [20] Lee, H. G., and Cowman, M. K. (1994) *Anal. Biochem.* 219,278-287.
- [21] Albert DORFMAN, MELVIN L. OTT, e Richard WHITNEY, Febbraio 20, 1948.
- [22] Killmann, H., Benz, R., and Braun, V. (1996). Properties of the FhuA channel in the *Escherichia coli* outer membrane after deletion of FhuA portions within and outside the predicted gating loop. *J Bacteriol* 178, 6913-20.
- [23] The *Bacillus subtilis* centred wiki SubtiWiki: A community curated consensual annotation that is continuously updated. SubtiPathways is a model of *B.subtilis* metabolism and regulation in SBML/SBGN (Systems Biology Markup Language/ Graphical Notation).
- [24] Perkins JD, et al. XbaI and BlnI genomic cleavage maps of *Escherichia coli* K-12 strain MG1655 and comparative analysis of other strains. *J. Mol. Biol.* 232: 419-445, 1993.
- [25] Heath JD, et al. NotI genomic cleavage map of *Escherichia coli* K-12 strain MG1655. *J.Bacteriol.*174:558-567,1992.

[26] Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

[27] Weiner, M. P., Anderson, C., Jerpseth, B., Wells, S., Johnson-Browne, B. et al. (1994) Strategies 7(2):41-43.

[28] Altschul et al., 1997.

[29] Lederberg, J and Lederberg, EM (1952) Replica plating and indirect selection of bacterial mutants. J Bacteriol. 63: 399-406.

CLAIMS

1. Method for the production of hyaluronidase from *Streptomyces koganeiensis* ATCC 31394 comprising the amino acid sequence shown in SEQ. ID. No. 21 comprising the following steps:

a) inoculating a bacterial culture medium in a bioreactor with an inoculum of recombinant cells that contain at least one vector comprising the sequence shown as SEQ ID No. 41;

b) subjecting the content of the bioreactor of step a) to fermentation at a pH between 6.7 and 7.1 in the presence of a nourishment solution;

c) adding an inducer of the lac genes to the mixture of step b);

d) subjecting the mixture of step c) to an induction period of between 8 and 24 hours;

e) centrifuging the bacterial cells obtained in step d);

f) re-suspending the pellets obtained in step e) and subjecting the resulting suspension to osmotic shock;

g) extracting the periplasmic proteins by centrifugation of the suspension of step f);

h) purifying the protein fraction having hyaluronidase enzymatic activity obtained in step g) by a sequence of:

i. strong ion-exchange chromatography and isolation of the hyaluronidase enzymatic activity fraction;

ii. weak cation-exchange chromatography and isolation of the hyaluronidase enzymatic activity fraction;
and

iii. aromatic hydrophobic interaction chromatography and isolation of the hyaluronidase enzymatic activity fraction.



2. Method according to claim 1, wherein the recombinant cell of step a) is selected from a cell of *Escherichia coli* and one of *Bacillus subtilis*.
3. Method according to one of the preceding claims, wherein in step b), a glycerol solution is used as nourishment solution.
4. Hyaluronidase from *Streptomyces koganeiensis* ATCC 31394 in purified form and comprising the amino acid sequence in SEQ. ID. No. 21.
5. A polynucleotide comprising the nucleotide sequence shown in SEQ. ID. No. 17 encoding a bacterial hyaluronidase comprising the amino acid sequence in SEQ. ID. No. 21.
6. A genetically engineered recombinant vector comprising the polynucleotide according to claim 5.
7. A vector according to claim 6, wherein the vector is a plasmid.
8. A host cell comprising the vector according to one of claims 6 or 7.
9. A composition suitable for pharmaceutical or cosmetic use comprising the hyaluronidase according to claim 4.
10. The hyaluronidase according to claim 4, or obtainable by the method of claim 1, for use in the treatment and/or prevention of a disease or disorder, optionally in combination with at least another active principle.
11. The hyaluronidase for use according to claim 10, wherein the disorder or disease are at least one selected among oedemas, inflammatory conditions, chilblains, solid tumors, IgE-mediated allergies, diseases of the oral cavity, spontaneous vitreous haemorrhages, arteriosclerosis, blood pressure disorders, cardio-

cerebro vascular disorders such as brain arterial stenosis or stroke or bovine mastitis.

12. Non-therapeutic use of the hyaluronidase according to claim 4, or obtainable by the method of claim 1, for cosmetic applications and/or to improve the aesthetic appearance.

13. A hyaluronidase from *Streptomyces koganeiensis* ATCC 31394 comprising the amino acid sequence in SEQ. ID. No. 21 obtainable by the method of claim 1-3.

Fig.1



T1, T2, T3, T4, processed by RNA purification

T1, T2, T4, T5, processed by DNA extraction


Fig.2

1	<u>GAG AAC GGG GGG ACG ACG TTC GAC GGC CCG GTG GGC GGC GAG</u>	45
1	E N G A T T T F D G P V A A E	15
46	AGG TTC AGC GCG GAC ACC ACA CTG GAG GGC GGC TTC CTC AAG ACG	90
16	R F S A D T T L E A A P L K T	30
91	ACC TCG GAG ACG AAC CAC GCG GCG ACC ATC TAC CAG GGC GGT ACG	135
31	T S E T N H A A T I Y <u>Q</u> A G T	45
136	TOG GGC GAC GGC GCG GCG CTG AAC GTG ATC TOG GAC AAC CCG GGC	180
46	S G D G A A L N V I S D N P G	60
181	ACC TCG GGC ATG TAC CTC TCG GGC ACC GAG ACC GCG CCG GGC ACC	225
61	T S A M Y L S G T E T A R G T	75
226	CTG AAG ATC ACC CAC CCG GGG TAC GGC GAC GGC TCG GAC AAG GAC	270
76	L K I T H R G Y A D G S D K D	90
271	GCC GGC GGC CTG TCG CTC GAC CTC CCG GTG GGC GGC ACC GGC GGC	315
91	A A A L S L D L R V A G T A A	105
316	CAG GGC ATC TAC GTC ACG GCG ACG AAC GGC CCG ACC AAG GGC AAC	360
106	Q G I Y V T A T N G P T K G N	120
361	CTG ATC GGC CTG CCG AAC AAC ACG GGC CTG GAC GAC TTC GTC GTC	405
121	L I A L R N N T G L D D F V V	135
406	AAG GGC ACC GGC CCG ATC GGC GTC GGC ATC GAC CCG GCG GCC ACG	450
136	K G T G R I G V G I D R A A T	150
451	CCG CCG GGC CAG GTC CAG ATC GTC CAG CCG GGC GAC GGC CTC GGC	495
151	P R A Q V H I V Q R G D A L A	165
496	GCG CTC CTG GTG GAG GGC TOG GTA CCG <u>ATC GGG AAC GCG GCG ACG</u>	540
166	A L L V E G S V R <u>I G N A A T</u>	180
541	<u>GTG CCG</u> 546	
181	V P	

Besides the difference of an aminoacid (underlined) all the sequences obtained by the previous proteic sequences (in bold characters) were found.


Fig. 3

a) GENOME ENZYMATIC DIGESTION



X : PUTATIVE RESTRICTION SITE PER ENZYME

b) LIGATION OF THE DIGESTED ENZYME



**c) AMPLIFICATION WITH PRIMER
INTERNAL TO THE KNOWN REGION**




Fig.4

4/29

1	<u>ggta cct</u> gtg acg gct aca ccc cgc ccc aac ctc cgt aca acc att	45
1		15
46	ccgg agt tga tgc ttg tgc ttg tcc cgg ggg act cat gcg act cat	90
16		30
91	gcg tcc ctc cgt tca cag cag aca cga gag agt ggg gga cga cgc	135
31		45
136	ATG CCG GTG GCA CGC AGA CTG TTT CTG GGG AGC TTC ACC GCG GGC	180
46	M P V A R R L F L G S F T A G	60
181	GCG GTG ACC GTG GCG ACG GCC GCC GCG ACG GGT ACG GCC TCG GCG	225
61	A V T V A T A A A T G T A S A	75
226	GCC GGG <u>GAG AAC</u> ^{MesFor2} <u>GCG ACG ACC</u> TTC GAC GGC CCG GTG GCC	270
76	A G <u>E N</u> G A T T T F D G P V A	90
271	GCC GAG AGG TTC AGC GCG GAC ACC ACA CTG GAG GCC GCC TTC CTC	315
91	A E R F S A D T T L E A A F L	105
316	AAG ACG ACC TCG GAG ACG AAC CAC GCG GCG ACC ATC TAC CAG GCC	360
106	K T T S E T N H A A T I Y <u>Q</u> A	120
361	GGT ACG TCG GGC GAC GGC GCG GCG CTG AAC GTG ATC TCC GAC AAC	405
121	G T S G D G A A L N V I S D N	135
406	CCG GGC ACC TCG GCC ATG TAC CTC TCC GGC ACC GAG ACC GCG CGC	450
136	P G T S A M Y L S G T E T A R	150
451	GGC ACC <u>CTG AAG ATC ACC CAC</u> ^{MesINTR} <u>CGC GGG TAC GCC</u> GAC GGC TCC GAC	495
151	G T L K I T H R G Y A D G S D	165
496	AAG GAC GCC GCC GCC CTG TCG CTC GAC CTC CGC GTG GCC GGC ACC	540
166	K D A A A L S L D L R V A G T	180
541	GCC GCC CAG <u>GGC ATC TAC GTC ACG GCG ACG AAC</u> ^{MesINTf} GGC CCG ACC AAG	585
181	A A Q G I Y V T A T N G P T K	195
586	GGC AAC CTG ATC GCC CTG CGC AAC AAC ACG GGC CTG GAC GAC TTC	630
196	G N L I A L R N N T G L D D F	210
631	GTC GTC AAG GGC ACC GGC CGC ATC GGC GTC GGC ATC GAC CGC GCG	675
211	V V K G T G R I G V G I D R A	225
676	GCC ACG CCC CGC GCC CAG GTC CAC ATC GTC CAG CGG GGC GAC GCC	720
226	A T P R A Q V H I V Q R G D A	240
721	CTC GCC GCG CTC CTG GTG GAG GGC TCG GTA CGC ATC GGG AAC GCC	765
241	L A A L L V E G S V R I G N A	255
766	GCG ACG <u>GTA CCG</u> ACG TCG GTG GAC AGC TCG GGC GGC GGC GCC CTG	810
256	A T <u>V P</u> T S V D S S G G G A L	270
811	TAC GCG TCG GGC GGC GCC CTG CTG TGG CGC GGC TCC AAC GGC ACG	855
271	Y A S G G A L L W R G S N G T	285
856	GTC ACG ACG ATC GCA CCG GCG tga agt aca gga gag aac agt gca	900
286	V T T I A P A *	300
901	gtt gac gcc cga aga act gtt tgc cgg gag 930	
301		

Nucleic acids:

- In small letters the not encoding region found in 5' and in 3'.
- In italic letters the encoding region in 5' and 3' found with these last processing steps.
- In bold letters the START and STOP codons.
- In underlined letters the sequence corresponding to oligo in 5' MesFor2 (in bold letters the nucleotidic and conservative sequences) and MesINTf/MesINTR.
- In underlined and bold letters the restriction sites per KpnI.

Aminoacids:

- In bold letters the region corresponding to the results of the previous proteic sequencing.
- In bold letters the regions corresponding to the leader peptide found in this last processing step.

Fig.5

3	acc att cgg agt tga tog ttg tgc ttg tcc cgg ggg act cat gcg	47
0		14
48	act cat gcg tcc ctc cgt tca cag cag aca cga gag agt ggg gga	92
15		29
93	cga cgc ATG CCG GTG GCA CGC AGA CTG TTT CTG GGG AGC TTC ACC	137
30	<u>M P V A R R L F L G S F T</u>	44
138	GCG GGC GCG GTG ACC GTG GCG ACG GCC GCC GCG ACG GGT ACG GCC	182
45	<u>A G A V T V A T A A A T G T A</u>	59
183	TCG GCG GCC GGG GAG AAC GGC GCG ACG ACG ACC TTC GAC GGC CCG	227
60	<u>S A A G E N G A T T T F D G P</u>	74
228	GTG GCC GCC GAG AGG TTC AGC GCG GAC ACC ACA CTG GAG GCC GCC	272
75	V A A E R F S A D T T L E A A	89
273	TTC CTC AAG ACG ACC TCG GAG ACG AAC CAC GCG GCG ACC ATC TAC	317
90	F L K T T S E T N H A A T I Y	104
318	CAG GCC GGT ACG TCG GGC GAC GGC GCG GCG CTG AAC GTG ATC TCC	362
105	Q A G T S G D G A A L N V I S	119
363	GAC AAC CCG GGC ACC TCG GCC ATG TAC CTC TCC GGC ACC GAG ACC	407
120	D N P G T S A M Y L S G T E T	134
408	GCG CGC GGC ACC CTG AAG ATC ACC CAC CGC GGG TAC GCC GAC GGC	452
135	A R G T L K I T H R G Y A D G	149
453	TCC GAC AAG GAC GCC GCC GCC CTG TCG CTC GAC CTC CGC GTG GCC	497
150	S D K D A A A L S L D L R V A	164
498	GGC ACC GCC GCC CAG GGC ATC TAC GTC ACG GCG ACG AAC GGC CCG	542
165	G T A A Q G I Y V T A T N G P	179
543	ACC AAG GGC AAC CTG ATC GCC CTG CGC AAC AAC ACG GGC CTG GAC	587
180	T K G N L I A L R N N T G L D	194
588	GAC TTC GTC GTC AAG GGC ACC GGC CGC ATC GGC GTC GGC ATC GAC	632
195	D F V V K G T G R I G V G I D	209
633	CGC GCG GCC ACG CCC CGC GCC CAG GTC CAC ATC GTC CAG CGG GGC	677
210	R A A T P R A Q V H I V Q R G	224
678	GAC GCC CTC GCC GCG CTC CTG GTG GAG GGC TCG GTA CGC ATC GGG	722
225	D A L A A L L V E G S V R I G	239
723	AAC GCC GCG ACG GTA CCG ACG TCG GTG GAC AGC TCG GGC GGC GGC	767
240	N A A T V P T S V D S S G G G	254
768	GCC CTG TAC GCG TCG GGC GGC GCC CTG CTG TGG CGC GGC TCC AAC	812
255	A L Y A S G G A L L W R G S N	269
813	GGC ACG GTC ACG ACG ATC GCA CCG GCG tga agt aca gga gag aac	857
270	G T V T T I A P A *	284
858	agt gca gtt gac	869
285		288

- in underlined letters the region corresponding to the leader peptide.
- in bold letters the aminoacidic sequence corresponding to mature hyaluronidase.
- in bold and small letters the nucleotidic sequence of the primers utilized for the isolation.


Fig.6 (a)

CLUSTAL 2.1 multiple sequence alignment

S.pristinaespiralis	MSVSRRLFLGGFTAGAVIVAAGAAATPAAAAEADGFITTEGDFVVAEGERTIDSTVKSATF 60
S.tsukubaensis	MAVNRRLFLGGFTAGAVIVAAG-TATPAAAAAQGFITTEGDFVVAERFSTINSTVNSAFL 59
S.koganeiensis	MPVARRLFLGSSFTAGAVIVAATAAATGIASAAGENGATTTEGDFVVAERFSADITLEAAFL 60
Actinoplanes	MAMARRLFLGSSFTAGAVIVALGEST---PAAAEI-TITTEGDFVVAQRFSTIDSTIESAYF 56
	*.: *****.***** . :. ** .**** *.*: * :.:*::*:::
S.pristinaespiralis	KTTSTTEHAAVTAAYQAGTSGSGVALNWVSKNPGDSAMYLSGTEKAGTILKISHIGHADGSD 120
S.tsukubaensis	KTTSTTEHAAVTVYQAGTSGSGVALNIVSDNPDNSAVYLTGREKIRGTILKISHIGHADGSD 119
S.koganeiensis	KTTSETNHAATVYQAGTSGDGAALNWVSDNPGTSAMYLSGTETARGTILKITHRGYADGSD 120
Actinoplanes	KTTSVIDNAVTVYQAASGRGVALNWVSDNPEENSAMYLEGTETGRGTILKITHRQGYDQSD 116
	**** *.:*.* ***.*** *.*::*.* **.* * * .*****.* * :****
S.pristinaespiralis	EKASALSIDLRTAGTAAQGIYVIAATNGFTKGNLIALRNNTGLDDFVVKETGRIGVGDRA 179
S.tsukubaensis	ADAAAVSIDLKTATQGIIFLTATDGAATGNLIALRNNTGRDDFVVKSGRIGVGLAVG 178
S.koganeiensis	KDAAALSDDLRVAGTAAQGIYVIAATNGFTKGNLIALRNNTGLDDFVVKETGRIGVGDRA 180
Actinoplanes	RSAAALSIDLRTAGTAAQGIYVIAATNGFTKGNLIALRNNTGRDDFVVKETGRIGVGNRG 176
	.:.* **.*::*.* *.*.*.*.***** .*****.*.*::*.*:
S.pristinaespiralis	GNPWSQLHVQQPGTDSALMVEGIVRVVDVASAFTGVDSRGGGVLYAENGALKWRGSDNT 239
S.tsukubaensis	SAPWSQLHVQQRPGDASALMVEGAVRIVDAATVFTAVDSKGGGILYAQGGELMWRASANGN 238
S.koganeiensis	ATPRAQVHIVQRGDALALLVEGSRVIGNAATVFTSVDSSGGGALYASGGALLWRGSDNGT 240
Actinoplanes	DTPRQVHIVQQPGVPAVGLIEGVVRIANTATVFTSADSSGGGNLYAVNGALMWRASANGK 236
	* .*:***: . . :.:*** ** :.:*.*.* ** ** * * * * .:..
S.pristinaespiralis	VITIAPA 246
S.tsukubaensis	VIRIASA 245
S.koganeiensis	VITIAPA 247
Actinoplanes	VIQIASA 243
	** **.*

- Bacterial hyaluronidase (Hyaluronidase_1) functional domain
- * Conserved aminoacidic residues
- : Aminoacidic residues with strongly similar properties
- . Aminoacidic residues with strongly similar properties

Fig.7 (a)



Aminoacidic sequence of Hyaluronidase from *S. Koganeiensis*:






Fig.7 (b)


Hyaluronoglucosaminidase YP_006266806.1 of *Actinoplanes* sp. SE50/110



predicted protein ZP_06911952.1 of *Streptomyces pristinaespiralis* ATCC 25486



hypothetical protein ZP_10072726.1 of *Streptomyces tsukubaensis* NRRL 18488



10/29

Fig.8






Fig.9

(a)



Marker
ΦX174
DNA

(b)



- 1- pHTsk_HYAL digested with *BamHI-XbaI*
- 2- pHYAL_sk_SL digested with *NdeI-EcoRI*
- 3- pHYAL_sk digested with *NcoI-EcoRI*

Fig.10




Fig.11




Fig.12




Fig.13 (a)

[pHTsk_HYAL]

2601	AAGGATCAAT GATTCAAAAA CGAAAGCGGA CAGTTTCGTT CAGACTTGTG CTTATGTGCA CGCTGTTATT TGTCAGTTG CCGATTACAA AAACATCAGC TTCCTAGTTA CTAAGTTTTT GCTTTCGCCT GTCAAAGCAA GTCTGAACAC GAATACACGT GCGACAATAA ACAGTCAAAC GGCTAATGTT TTTGTAGTCG
	BamHI *****
+2	A G E N G A T T T F D G P V A A E R F S A D T T L E A A F L
2701	CGTAGGATCC GCGGGGAGA ACGGCGGCAC GACGACCTC GACGGCCCGG TGGCCGCCGA GAGGTTCAGC GCGGACACCA CACTGGAGGC CGCCTTCCTC GCATCCTAGG CCGCCCCCTCT TGCCGCGCTG CTGCTGGAAG CTGCCGGGCC ACCGGCGGCT CTCCAAGTCG CGCCTGTGTT GTGACCTCCG GCGGAAGGAG
+2	K T T S E T N H A A T I Y Q A G T S G D G A A L N V I S D N P G T S
2801	AAGACGACCT CGGAGACGAA CCACGCGGCG ACCATCTACC AGGCCGGTAC GTCGGGCGAC GCGCGGGCGC TGAACGTGAT CTCCGACAA CCGGGCACCT TTCTGCTGGA GCCTCTGCTT GGTGCGCCGC TGGTAGATGG TCCGGCCATG CAGCCCGCTG CCGCGCCGCG ACTTGCACTA GAGGCTGTTG GGCCCGTGGA
+2	S A M Y L S G T E T A R G T L K I T H R G Y A D G S D K D A A A L S
2901	CGGCCATGTA CCTCTCCGGC ACCGAGACCG CCGCGGCGAC CCTGAAGATC ACCCACCGG GGTACGCCGA CGGCTCCGAC AAGGACGCG CCGCCTGTC GCCGGTACAT GGAGAGGCGG TGGCTCTGGC GCGCGCCGTG GGACTTCTAG TGGGTGGCGC CCATGCGGCT GCCGAGGCTG TTCCTGCGGC GCGGGGACAG
+2	S L D L R V A G T A A Q G I Y V T A T N G P T K G N L I A L R N N T
3001	GCTCGACCTC CGCGTGGCCG GCACCGCCGC CCAGGGCATC TACGTCACGG CGACGAACGG CCCGACCAAG GGCAACCTGA TCGCCCTGCG CAACAACACG CGAGCTGGAG GCGCACCGGC CGTGGCGGCG GGTCCCGTAG ATGCACTGCC GCTGCTTGGC GGGCTGTTTC CCGTGGACT AGCGGGACGC GTTGTGTGTC
+2	G L D D F V V K G T G R I G V G I D R A A T P R A Q V H I V Q R G D
3101	GGCCTGGACG ACTTCGTCGT CAAGGGCACC GGCCGCATCG GCGTCGGCAT CGACCGCGCG GCCACGCCCC GCGCCAGGT CCACATCGTC CAGCGGGGCG CCGGACCTGC TGAAGCAGCA GTTCCCGTGG CCGCGGTAGC CGCAGCCGTA GCTGGCGCGC CGGTGCGGGG CGCGGGTCCA GGTGTAGCAG GTCGCCCCGC
+2	D A L A A L L V E G S V R I G N A A T V P T S V D S S G G G A L Y A
3201	ACGCCCTCGC CGCGCTCCTG GTGGAGGGCT CGGTACGCAT CCGGAACGCC GCGACGGTAC CGACGTCGGT GGACAGCTCG GCGGCGGCG CCCTGTACGC TGCGGGAGCG GCGCGAGGAC CACCTCCGA GCCATGCGTA GGCCTTGGCG CGCTGCCATG GCTGCAGCCA CCTGTGAGC CCGCGCGCG GGGACATGCG
	XbaI *****
+2	A S G G A L L W R G S N G T V T T I A P A *
3301	GTCGGGCGGC GCCCTGCTGT GCGCGGCTC CAACGGCAGC GTCACGACGA TCGACCGGC GTGATCTAGA GTCGACGTCC CCGGGGACG CCGCCTAATG CAGCCCGCGC CCGGACGACA CCGCGCCGAG GTTCCCGTGC CAGTGTGCT AGCGTGGCCG CACTAGATCT CAGCTGCAGG GGCCCCGTCG GCGGGATTAC



Sequence belonging to Vector pHT43

Fig.13 (b)

[pHyal_sk]

5101	CTCGATCCCG CGAAATTAAT ACGACTCACT ATAGGGGAAT TGTGAGCGGA TAACAATTCC CCTCTAGAAA TAATTTTGTT TAACTTTAAG AAGGAGATAT GAGCTAGGGC GCTTTAATTA TGCTGAGTGA TATCCOCTTA ACACTCGCCT ATTGTTAAGG GGAGATCTTT ATTAAAACAA ATTGAAATTC TTCCTCTATA
	NcoI ~~~~~ A G E N G A T T T
+3	
5201	ACATATGAAA TACCTGCTGC CGACCGCTGC TGCTGGTCTG CTGCTCCTCG CTGCCAGCC GGCATGGCC ATG CGCCGGG AGAACGGCGC GACGACGACC TGTATACTTT ATGGACGACG GCTGGCGACG ACGACCAGAC GACGAGGAGC GACGGGTCGG CCGTACCAGG TAC CGGCCCC TCTGCGCGG CTGCTGCTGG
+3	F D G P V A A E R F S A D T T L E A A F L K T T S E T N H A A T I Y
5301	TTCGACGGCC CGGTGGCCGC CGAGAGGTTG AGCGCGGACA CCACACTGGA GGCCGCCTTC CTCAGACGA CCTCGGAGAC GAACCACGCG GCGACCATCT AAGTGCCGG GCCACCGGG GCTCTCCAAG TCGCGCCTGT GGTGTGACCT CCGCGGGAAG GAGTCTGCT GGAGCCTCTG CTTGGTGC GCCTGGTAGA
+3	· Y Q A G T S G D G A A L N V I S D N P G T S A M Y L S G T E T A R G ·
5401	ACCAGGCCGG TACGTCGGGC GACGGCGCGG CGCTGAACGT GATCTCCGAC AACCCGGGCA CCTCGGCCAT GTACTCTCC GGCACCGAGA CCGCGCGCGG TGGTCCGGCC ATGCAGCCCG CTGCCGCGCC GCGACTTGA CTAGAGGCTG TTGGGCCCGT GGAGCCGGTA CATGGAGAGG CCGTGGCTCT GCGCGCGGCC
+3	· G T L K I T H R G Y A D G S D K D A A A L S L D L R V A G T A A Q G ·
5501	CACCCGTAAG ATCACCACC GCGGTACGC CGACGGCTCC GACAAGGACG CCGCCGCCCT GTCGCTCGAC CTCGCGTGG CCGGCACCGC CGCCAGGGC GTGGACTTC TAGTGGGTGG CGCCATGCG GGTGCGGAG CTGTTCTCTG GCGCGGGA CAGCGAGCTG GAGGCGCACC GGCGGTGGC GCGGGTCCG
+3	I Y V T A T N G P T K G N L I A L R N N T G L D D F V V K G T G R I
5601	ATCTACGTCA CGGCAGGAA CGGCCGACC AAGGGCAACC TGATGCCCT GCGCAACAAC ACGGCGCTGG ACGACTTCTG CTTCAAGGGC ACCGGCCGCA TAGATGCACT GCCGCTGCTT GCGGGCTGG TTCCCGTTGG ACTAGCGGGA CCGTGTGTTG TGCCCGGACC TGCTGAAGCA GCAGTTCCCG TGGCCGGCGT
+3	· I G V G I D R A A T P R A Q V H I V Q R G D A L A A L L V E G S V R ·
5701	TCGGCGTCGG CATCGACCGC GCGGCCACGC CCCGCGCCA GGTCCACATC GTCCAGCGGG GCGACGCCCT CGCCGCGCTC CTGGTGGAGG GCTCGGTACG AGCCGACGCC GTAGCTGGCG CGCCGGTGG GGGCGGGGT CCAGGTGTAG CAGGTGCGCC CGCTGCGGGA GCGCGCGGAG GACCACCTCC CGAGCCATGC
+3	R I G N A A T V P T S V D S S G G G A L Y A S G G A L L W R G S N G
5801	CATCGGGAAC GCGCGACGG TACCGACGTC GGTGGACAGC TCGGCGGGC GCGCCCTGTA CGGTCGGGC GCGCCCTGC TGTGGCGCGG CTCCAACGGC GTAGCCCTTG CCGCGCTGCC ATGGCTGCAG CCACCTGTCG AGCCCGCCG CCGGGGACAT GCGCAGCCCG CCGCGGGACG ACACCGCGCC GAGGTTGCCG
	EcoRI ~~~~~
+3	T V T T I A P A *
5901	ACGGTCACGA CGATCGCACC GCGGTGAGAA TTCGAGCTCC GTCGACAAGC TTGCGGCCGC ACTCGAGCAC CACCACCACC ACCACTGAGA TCCGGCTGCT TGCCAGTCTGCT GCTAGCGTGG CCGCACTCTT AAGCTCGAGG CAGCTGTTCG AACGCGGGC TGAGCTCGTG GTGGTGGTGG TGGTACTCT AGGCCGACGA
6001	AACAAAGCCC GAAAGGAAGC TGAGTTGGCT GCTGCCACCG CTGAGCAATA ACTAGCATAA CCCCTTGGGG CCTCTAAACG GGTCTTGAGG GGTTTTTTGC TTGTTTCGGG CTTTCCTTCG ACTCAACCGA CGACGGTGGC GACTCGTTAT TGATCGTATT GGGGAACCCC GGAGATTTC CCAGAACTCC CCAAAAACG
6101	TGAAAGGAGG AACTATATCC GGAT ACTTTCCTCC TTGATATAGG CCTA

Sequence belonging to Vector : pET22b (+)

Fig.13 (c)

[pHyal_sk_SL]

5101	CTCGATCCCG CGAAATTAAT ACGACTCACT ATAGGGGAAT TGTGAGCGGA TAACAATTCC CCTCTAGAAA TAATTTTGT TAACTTTAAG AAGGAGATAT GAGCTAGGGC GCTTTAATTA TGCTGAGTGA TATCCCTTA ACACTCGCCT ATTGTTAAGG GGAGATCTTT ATTAATAACAA ATTGAAATTC TTCCCTATA
	NdeI ~~~~~
+3	A G E N G A T T T F D G P V A A E R F S A D T T L E A A F L K
5201	ACATATGCC GGGGAGAACG GCGCGACGAC GACCTTCGAC GGCCCGTGG CCGCCGAGAG GTTCAGCGCG GACACCACAC TGGAGGCCCG CTCCTCAAG TGTATAACGG CCCCTCTTGC CCGCTGCTG CTGGAAGCTG CCGGGCCACC GCGGCTCTC CAAGTCGCGC CTGTGCTGTG ACCTCCGGCG GAAGGAGTTC
+3	T T S E T N H A A T I Y Q A G T S G D G A A L N V I S D N P G T S A
5301	ACGACCTCGG AGACGAACCA CGCGCGGACC ATCTACCAGG CCGGTACGTC GGGCGACGGC GCGGCGTGA ACGTGATCTC CGACAACCCG GGCACCTCGG TGCTGGAGCC TCTGCTTGGT GCGCGCTGG TAGATGGTCC GGCCATGCAG CCCGCTGCC GCGCCGCACT TGCAC TAGAG GCTGTTGGGC CCGTGGAGCC
+3	A M Y L S G T E T A R G T L K I T H R G Y A D G S D K D A A A L S L
5401	CCATGTACCT CTCGGCACC GAGACCGCGC GCGGCACCCT GAAGATCACC CACCGCGGGT ACGCCGACGG CTCGGACAAG GACGCCGCCG CCCTGTCGCT GGTACATGGA GAGGCCCTGG CTCTGGCGCG CCGCTGGGA CTCTAGTGG GTGGGCCCA TCGGCTGCC GAGGCTGTT CTGCGCGGC GGGACAGCGA
+3	L D L R V A G T A A Q G I Y V T A T N G P T K G N L I A L R N N T G
5501	CGACCTCCGC GTGGCCGCA CCGCCGCCA GGCATCTAC GTCACGGCGA CGAACGGCC GACCAAGGGC AACCTGATCG CCCTGCCAA CAACACGGGC GCTGGAGCG CACCGGCCG GCGCGCGGT CCGTAGATG CAGTGCCTGCT GCTTCCGGG CTGCTCCCG TTGGACTAGC GGGACCGCTT GTTGTGCCCG
+3	L D D F V V K G T G R I G V G I D R A A T P R A Q V H I V Q R G D A
5601	CTGGACGACT TCGTCGTC A GGGACCGGC CGCATCGGC TCGGCATCGA CCGCGCGGC ACGCCCGCG CCCAGGTCCA CATCGTCCAG CGGGGCAGC GACCTGCTGA AGCAGCAGTT CCCGTGGCG GCGTAGCCG AGCCGTAGCT GCGCGCGCG TCGGGGCGG GGTCCAGGT GTAGCAGGTC GCCCGCTGC
+3	A L A A L L V E G S V R I G N A A T V P T S V D S S G G G A L Y A S
5701	CCCTCGCGC GCTCCTGTTG GAGGGCTCG TACGCATCG GAACGCCCG ACGGTACCGA CGTCGGTGA CAGCTCGGC GCGGGGCC TGTACCGTTC GGGAGCGCG CGAGGACCAC CTCCGAGCC ATGCGTAGCC CTGCGCGCG TGCCATGGCT GCAGCCACCT GTCGAGCCCG CCGCCGCGG ACATGCGCAG
	EcoRI ~~~~~
+3	S G G A L L W R G S N G T V T T I A P A *
5801	GGCGCGGCC CTGCTGTGG CCGGCTCAA CGGCACGGTC ACGACGATCG CACCGCGTG AEAATTCGAG CTCCTCGAC AAGCTTGGG CCGCACTCGA CCCGCCCGG GACGACCCG CCGGAGGTT GCGTGCAG TGCTGCTAGC GTGGCCGAC TCTTAAGCTC GAGGCAGCT TTCGAACGCC GCGGTGAGCT
5901	GCACCACCAC CACCACCCT GAGATCCGC TGCTAACAA GCCCGAAAG AAGCTGAGTT GGCTGCTGCC ACCGTGAGC AATAACTAGC ATAACCCCTT CGTGGTGGT GTGGTGGTGA CTCTAGGCC ACGATTGTTT CCGGCTTTC TTCGACTCAA CCGACGACG TGGCGACTCG TTATTGATCG TATTGGGGAA



Sequence belonging to Vector PET21b(+)

Fig.14




Fig.15




Fig.16





Fig.17

(a)



(b)




Fig.18




Fig.19




Fig.20





Fig.21 (a)



(b)




Fig.22




Fig.23




Fig.24







Fig.25

Hyaluronidase activity inhibition from animal blood



Hyaluronidase activity inhibition from human blood



INTERNATIONAL SEARCH REPORT

International application No

PCT/IB2014/062193

A. CLASSIFICATION OF SUBJECT MATTER INV. C07K14/315 C12N9/26 ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) C07K C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, WPI Data, BIOSIS, EMBASE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2010/130810 A1 (FIDIA FARMACEUTICI [IT]; MESSINA LUCIANO [IT]; VACCARO SUSANNA [IT]; C) 18 November 2010 (2010-11-18)	4-11,13
Y	page 2, line 13 - page 15, line 13; claims 1-12; examples 1-3	1-3,12
X	EP 0 005 751 A1 (FUJISAWA PHARMACEUTICAL CO [JP]) 12 December 1979 (1979-12-12) cited in the application page 8, line 26 - page 20, line 15; claims 1-5	4,13
Y	WO 2009/111066 A1 (HALOZYME INC [US]; BAKER DAVID [US]; BOOKBINDER LOUIS [US]) 11 September 2009 (2009-09-11) examples 1-12	1-3,12
	----- -/--	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C.		<input checked="" type="checkbox"/> See patent family annex.
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report	
10 November 2014	17/11/2014	
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Westphal-Daniel, K	

INTERNATIONAL SEARCH REPORT

International application No

PCT/IB2014/062193

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CN 101 633 931 A (SHANDONG INST OF BIOLOG MEDICI) 27 January 2010 (2010-01-27) the whole document -----	1-3,12
Y	WO 2009/037566 A2 (UVARKINA TAMARA P [RU]; KAHOJAN EUGENE G [RU]) 26 March 2009 (2009-03-26) paragraph [0012] - paragraph [0372]; figure 1 -----	1-3,12
A	HYNES WAYNE L ET AL: "Hyaluronidases of Gram-positive bacteria", FEMS MICROBIOLOGY LETTERS, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 183, no. 2, 15 February 2000 (2000-02-15), pages 201-207, XP002538530, ISSN: 0378-1097, DOI: 10.1111/J.1574-6968.2000.TB08958.X the whole document -----	1-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2014/062193

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2010130810	A1	18-11-2010	CA 2759373 A1	18-11-2010
			CN 102439144 A	02-05-2012
			EP 2432874 A1	28-03-2012
			RU 2011150814 A	20-06-2013
			US 2012070441 A1	22-03-2012
			WO 2010130810 A1	18-11-2010

EP 0005751	A1	12-12-1979	DE 2962780 D1	01-07-1982
			EP 0005751 A1	12-12-1979
			JP S6033474 B2	02-08-1985
			JP S54147997 A	19-11-1979
			US 4258134 A	24-03-1981

WO 2009111066	A1	11-09-2009	CA 2717383 A1	11-09-2009
			CN 101970650 A	09-02-2011
			EP 2268805 A1	05-01-2011
			EP 2674487 A2	18-12-2013
			IL 207398 A	30-04-2014
			IL 223420 A	30-04-2014
			JP 2011512844 A	28-04-2011
			KR 20100135777 A	27-12-2010
			US 2011053247 A1	03-03-2011
			US 2012196348 A1	02-08-2012
			WO 2009111066 A1	11-09-2009

CN 101633931	A	27-01-2010	NONE	

WO 2009037566	A2	26-03-2009	RU 2010101892 A	27-07-2011
			RU 2012127988 A	10-01-2014
			US 2010172892 A1	08-07-2010
			US 2013189242 A1	25-07-2013
			WO 2009037566 A2	26-03-2009
